Methods and compositions for expressing negative-sense viral RNA in canine cells

ABSTRACT

The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.

1. CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119(e) of thefollowing U.S. Provisional Application Nos.: U.S. 60/793,522, filed Apr.19, 2006; U.S. 60/793,525, filed Apr. 19, 2006; U.S. 60/702,006, filedJul. 22, 2005; U.S. 60/699,556, filed Jul. 15, 2005; U.S. 60/699,555,filed Jul. 15, 2005; U.S. 60/692,965 filed Jun. 21, 2005; and U.S.60/692,978 filed Jun. 21, 2005. The priority applications are herebyincorporated by reference herein in their entirety for all purposes.

2. FIELD OF THE INVENTION

In one aspect, the present invention provides an isolated nucleic acidcomprising a canine RNA polymerase I regulatory sequence. In otheraspects, the invention provides expression vectors and cells comprisingsuch nucleic acids as well as methods of using such nucleic acids tomake influenza viruses, including infectious influenza viruses.

3. BACKGROUND

Influenza pandemics are defined by a dramatic global increase inmorbidity and mortality due to influenza illness. Several factorscombine to modulate the severity and extent of the pandemic includingthe low degree of immunity in the population and the efficiency withwhich the virus can transmit among humans. The latter is generallyinfluenced not only by the virus itself but the density of thepopulation and ease of travel into and out of a region. The virusresponsible for the pandemic is generally a recently emerged antigenicvariant that the majority of the population have not had priorexperience with and, therefore, have little or no immunity to. Inaddition, efficient human to human transmission is a prerequisite forrapid spread and, in the case of zoonotic introduction of animal virusesinto human populations, the virus must adapt to replication in humansand be capable of efficient transmission.

Pandemic influenza spreads very quickly and can have devastating impact.The most severe pandemic of the 20^(th) century, the 1918 pandemic,killed over 500,000 U.S. citizens and between 20 to 40 million peopleworldwide. The pandemic may produce waves of disease, with peaks ofincidence separated by several weeks to months. The relatively rapidonset and spread of pandemic influenza presents several problems forresponding to a global attack of this magnitude and imposes overwhelmingburdens on emergency responders and health care workers. Rapididentification and response to the emerging pandemic is clearly anecessary element of the solution; several programs are currently inplace worldwide to monitor emerging influenza viruses including avianinfluenza viruses that infrequently cause disease in humans. Thesesurveillance data are used in conjunction with predefined pandemic alertlevels in order to identify the likelihood of the threat and provideguidance for an effective response.

Vaccination is the most important public health measure for preventingdisease caused by annual epidemics of influenza. The short intervalbetween identification of a potential pandemic and the onset ofsignificantly increased disease levels present significant challengesfor producing sufficient vaccine to protect a large segment of thepopulation. Having vaccine technology and manufacturing infrastructurein place prior to the emergence of the next pandemic will be critical inameliorating a significant amount of illness and death. The shortresponse times needed to produce a “pandemic vaccine” will not allow forprolonged research or process development to be conducted in order toprovide an effective response.

To date, all commercially available influenza vaccines for non-pandemicstrains in the United States have been propagated in embryonated hen'seggs. Although influenza virus grows well in hen's eggs, production ofvaccine is dependent on the availability of eggs. Supplies of eggs mustbe organized, and strains for vaccine production selected months inadvance of the next flu season, limiting the flexibility of thisapproach, and often resulting in delays and shortages in production anddistribution. Unfortunately, some influenza vaccine strains, such as theprototype A/Fujian/411/02 strain that circulated during the 2003-04season, do not replicate well in embryonated chicken eggs, and have tobe isolated by cell culture in a costly and time consuming procedure.

Systems for producing influenza viruses in cell culture have also beendeveloped in recent years (See, e.g., Furminger. Vaccine Production, inNicholson et al. (eds) Textbook of Influenza pp. 324-332; Merten et al.(1996) Production of influenza virus in cell cultures for vaccinepreparation, in Cohen & Shafferman (eds) Novel Strategies in Design andProduction of Vaccines pp. 141- 151). Typically, these methods involvethe infection of suitable immortalized host cells with a selected strainof virus. While eliminating many of the difficulties related to vaccineproduction in hen's eggs, not all pathogenic strains of influenza growwell and can be produced according to established tissue culturemethods. In addition, many strains with desirable characteristics, e.g.,attenuation, temperature sensitivity and cold adaptation, suitable forproduction of live attenuated vaccines, have not been successfully grownin tissue culture using established methods.

In addition to cell culture-based methods that rely on infecting thecell culture with live virus, fully infectious influenza viruses havebeen produced in cell culture using recombinant DNA technology.Production of influenza viruses from recombinant DNA significantlyincreases the flexibility and utility of tissue culture methods forinfluenza vaccine production. Recently, systems for producing influenzaA and B viruses from recombinant plasmids incorporating cDNAs encodingthe viral genome have been reported See, e.g., Neumann et al. (1999)Generation of influenza A virus entirely from cloned cDNAs. Proc NatlAcad Sci USA 96:9345-9350; Fodor et al. (1999) Rescue of influenza Avirus from recombinant DNA. J. Virol 73:9679-9682; Hoffmann et al.(2000) A DNA transfection system for generation of influenza A virusfrom eight plasmids Proc Natl Acad Sci USA 97:6108-6113; WO 01/83794;Hoffmann and Webster (2000), Unidirectional RNA polymerase I-polymeraseII transcription system for the generation of influenza A virus fromeight plasmids, 81:2843-2847; Hoffmann et al. (2002), Rescue ofinfluenza B viruses from 8 plasmids, 99(17): 11411-11416; U.S. Pat. Nos.6,649,372 and 6,951,754; U.S. publication nos. 20050003349 and20050037487, which are incorporated by reference herein. These systems,often referred to as “plasmid rescue,” offer the potential to producerecombinant viruses expressing the immunogenic HA and NA proteins fromany selected strain.

However, these recombinant methods rely on use of expression vectorscomprising RNA polymerase I (RNA pol I) regulatory elements to drivetranscription of viral genomic rRNA. Such regulatory elements arenecessary to produce the defined 5′ and 3′ ends of the influenza genomicRNA such that a fully infectious influenza virus can be made. Currentrecombinant systems, such as those described above, use the human RNApol I regulatory system to express viral RNA. Because of the speciesspecificity of the RNA pol I promoter, these regulatory elements areonly active in human or primate cells. Thus, plasmid rescue of influenzavirus has to date been possible only by transfecting appropriateplasmids into human or primate cells.

Further, such human or primate cells frequently do not yield asufficient titer of influenza virus required for vaccine manufacture.Instead, Madin-Darby canine kidney cells (MDCK cells) can be used toreplicate vaccine strains to a sufficient titer to manufacturecommercial vaccines. Thus, production of an influenza vaccine usingplasmid rescue presently requires use of at least two different cellcultures. Identification and cloning of the canine RNA pol I regulatorysequences would allow plasmid rescue to be performed in the same cellculture as viral replication, eliminating the need for a separate rescueculture. As such, there remains a need for identification and cloning ofcanine RNA pol I regulatory elements which can be utilized to constructappropriate vectors for plasmid rescue in MDCK and other canine cells.These and other unmet needs are provided by the present invention.

Citation or discussion of a reference herein shall not be construed asan admission that such is prior art to the present invention. Inaddition, citation of a patent shall not be construed as an admission ofits validity.

4. SUMMARY

Disclosed herein are nucleic acids which comprise regulatory elementsthat can be used to express, for example, influenza genomic RNA incanine cells. Compositions such as isolated nucleic acids, vectors, andcells comprising the canine regulatory sequences of the invention, andmethods of using the same are embodiments of the subject invention.

Accordingly, in certain aspects, isolated nucleic acids of the inventioncomprise a canine RNA polymerase I (pol I) regulatory sequence. Incertain embodiments, the regulatory sequence comprises a promoter. Incertain embodiments, the regulatory sequence comprises an enhancer. Incertain embodiments, the regulatory sequence comprises both a promoterand an enhancer. In one embodiment, the regulatory sequence comprisesnucleotides −250 to −1 (in relation to the first nucleotide transcribedfrom the promoter, also known as the +1 nucleotide) of the correspondingnative promoter or a functional derivative thereof. In one embodiment,the regulatory sequence is operably linked to a viral DNA, e.g., acloned viral cDNA. In one embodiment, the cloned viral cDNA encodesviral RNA of a negative or positive strand virus or the correspondingcRNA. In certain embodiments, the cloned viral cDNA encodes genomicviral RNA (or the corresponding cRNA) of an influenza virus.

In one embodiment, isolated nucleic acids of the invention comprise acanine RNA polymerase I regulatory sequence and a transcriptionaltermination sequence. In certain embodiments, the transcriptionaltermination sequence is an RNA polymerase I termination sequence. In aspecific embodiment, the transcriptional termination sequence is ahuman, monkey, or canine pol I termination sequence.

In certain aspects, the present invention provides an isolated nucleicacid that comprises a canine RNA pol I promoter. Preferably, the canineRNA pol I promoter is operably linked to a nucleic acid to betranscribed, such as, e.g., an influenza genomic RNA. In one embodiment,introduction of the nucleic acid into a canine cell results intranscription of the influenza genomic RNA, and, in the presence ofsuitable influenza proteins, the RNA transcript can be packed into aninfectious influenza virus. In one embodiment, isolated nucleic acidsare provided which comprise a canine RNA regulatory sequence of theinvention (e.g., a canine RNA pol I promoter), wherein the regulatorysequence is operably linked to a nucleic acid to be transcribed and, inthe presence of suitable proteins (e.g., an RNP complex in the case of anucleic acid encoding a influenza vRNA segment) in vitro or in vivo, istranscribed. In one embodiment, the nucleic acid operably linked to saidregulatory sequence is an influenza vRNA segment.

In certain embodiments, nucleic acids of the invention comprise apolynucleotide sequence or a functionally active fragment thereof, e.g.,a canine RNA pol I regulatory sequence, that binds a human, primate,mouse or canine pol I polypeptide and is at least 100% or about 99%,98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, or 65% identical to one ormore nucleotide sequences selected from the group consisting of: SEQ IDNos: 1-19. In one embodiment, the polynucleotide sequence orfunctionally active fragment thereof further retains the ability toinitiate transcription, in the presence of appropriate polypeptides(e.g., human, primate, mouse or canine pol I polypeptides), of a secondpolynucleotide sequence operatively linked to the nucleotide sequence.In one embodiment, “functionally active fragments” of the nucleic acidsset forth in SEQ ID Nos: 1-19 retain one or more functional activitiesdescribed herein of the full length sequences of SEQ ID Nos: 1-19. Forinstance, functionally active fragments of the regulatory sequence setforth as SEQ ID NO: 1 are provided whereby the regulatory sequencefragment is operably linked to a nucleic acid to be transcribed and, inthe presence of suitable proteins in vitro or in vivo, is transcribed.

In certain embodiments, nucleic acids of the invention comprise apolynucleotide sequence or a fragment thereof, e.g., a canine RNA pol Iregulatory sequence, that binds a human, primate, mouse or canine pol Ipolypeptide and/or is 100% or at least or about 99%, 98%, 97%, 96%, 95%,90%, 85%, 80%, 75%, 70%, or 65% identical to one or more nucleotidesequences selected from the group consisting of: SEQ ID Nos: 1-19. Inone embodiment, the polynucleotide sequence or fragment thereof furtherretains the ability to initiate transcription, in the presence ofappropriate polypeptides (e.g., human, primate, mouse or canine pol Ipolypeptides), of a second polynucleotide sequence operatively linked tothe nucleotide sequence.

In other embodiments, isolated nucleic acids of the invention comprise acanine RNA polymerase I regulatory sequence and a ribozyme sequence.This may be, for example, the hepatitis delta virus genomic ribozymesequence or a functional derivative thereof.

In one embodiment, nucleic acids of the invention encode genomic viralRNA from any negative-strand RNA virus known by one of skill in the artwithout limitation. In certain embodiments, the viral RNA encodesgenomic viral RNA of a virus from the order Mononegavirales. In certainembodiments, the viral RNA encodes genomic viral RNA of a virus from thefamily Paramyxoviridae, Pneumovirinae, Rhabdoviridae, Filoviridae,Bomaviridae, Orthomyxoviridae, Bunyaviridae, or Arenaviridae. In certainembodiments, the viral RNA encodes genomic viral RNA of a virus from thegenus Respirovirus, Morbillivirus, Rubulavirus, Henipavirus, Avulavirus,Pneumovirus, Metapneumovirus, Vesiculovirus, Lyssavirus, Ephemerovirus,Cytorhabdovirus, Nucleorhabdovirus, Novirhabdovirus, Marburgvirus,Ebolavirus, Bomavirus, Influenzavirus A, Influenzavirus B,Influenzavirus C, Thogotovirus, Isavirus, Orthobunyavirus, Hantavirus,Nairovirus, Phlebovirus, Tospovirus, Arenavirus, Ophiovirus, Tenuivirus,or Deltavirus. In certain embodiments, the viral RNA encodes genomicviral RNA of a virus selected from the group consisting of Sendai virus,Measles virus, Mumps virus, Hendra virus, Newcastle disease virus, Humanrespiratory syncytial virus, Avian pneumovirus, Vesicular stomatitisIndiana virus, Rabies virus, Bovine ephemeral fever virus, Lettucenecrotic yellows virus, Potato yellow dwarf virus, Infectioushematopoietic necrosis virus, Lake Victoria marburgvirus, Zaireebolavirus, Boma disease virus, Influenza A virus, Influenza B virus,Influenza C virus, Thogoto virus, Infectious salmon anemia virus,Bunyamwera virus, Hantaan virus, Dugbe virus, Rift Valley fever virus,Tomato spotted wilt virus, Lymphocytic choriomeningitis virus, Citruspsorosis virus, Rice stripe virus, and Hepatitis delta virus.

In another aspect, the invention provides a vector comprising a nucleicacid of the invention. In certain embodiments, the vector is anexpression vector. In certain embodiments, the vector comprises abacterial origin of replication. In certain embodiments, the vectorcomprises a eukaryotic origin of replication. In certain embodiments,the vector comprises a selectable marker that can be selected in aprokaryotic cell. In certain embodiments, the vector comprises aselectable marker that can be selected in a eukaryotic cell. In certainembodiments, the vector comprises a multiple cloning site. In certainembodiments, the multiple cloning site is oriented relative to thecanine RNA polymerase I regulatory sequence to allow transcription ofpolynucleotide sequence introduced into the multiple cloning site fromthe regulatory sequence. In certain embodiments, vector comprises apolynucleotide sequence that can be expressed in canine cells, e.g., inMDCK cells.

In one embodiment, the invention provides expression vectors useful forrecombinantly rescuing a virus from cell culture, e.g., MDCK cellcultures. Generally, the vectors are useful for rescuing any virus knownto one skilled in the art to require production of RNA with defined endsduring its life-cycle. Such viruses include, but are not limited to,negative-sense strand RNA viruses, such as those described above.Preferably, the virus is an influenza virus, e.g., an influenza A,influenza B, or influenza C virus.

In certain embodiments, one or more of the vectors of the inventionfurther comprises a RNA transcription termination sequence. In certainembodiments, the transcription termination sequence is selected from thegroup consisting of a RNA polymerase I transcription terminationsequence, RNA polymerase II transcription termination sequence, RNApolymerase III transcription termination sequence, and a ribozyme.

In certain embodiments, the expression vectors are uni-directionalexpression vectors. In other embodiments, the expression vectors arebi-directional expression vectors. In some embodiments, thebi-directional expression vectors of the invention incorporate a firstpromoter inserted between a second promoter and a polyadenylation site,e.g., an SV40 polyadenylation site. In certain embodiments, the firstpromoter is a canine RNA pol I promoter. In certain embodiments, thesecond promoter is a canine RNA pol I promoter. In one embodiment, thefirst promoter and the second promoter can be situated in oppositeorientations flanking at least one cloning site.

In certain embodiments, the expression vectors comprise a ribozymesequence or transcription termination sequence 3′ of at least onecloning site relative to the canine RNA pol I promoter. In certainembodiments, the expression vectors comprise a ribozyme sequence ortranscription termination sequence 3′ of at least one cloning siterelative to the canine RNA pol I promoter such that vRNA can beintracellularly synthesized with exact 5′ and 3′ ends.

In one embodiment, in the bi-directional expression vectors of theinvention, a gene or cDNA is located between an upstream pol II promoterand a downstream canine pol I regulatory sequence (e.g., a pol Ipromoter) of the invention. Transcription of the gene or cDNA from thepol II promoter produces capped positive-sense viral mRNA andtranscription from the canine pol I regulatory sequence producesnegative-sense, uncapped vRNA. Alternatively, in a unidirectional vectorsystem of the invention, the gene or cDNA is located downstream of a polI and a pol II promoter. The pol II promoter produces cappedpositive-sense viral mRNA and the pol I promoter produces uncappedpositive-sense viral cRNA.

In another aspect, the invention provides a composition that comprisesone, two, three, four, five, six, seven, eight, nine, ten, eleven,twelve, thirteen, fourteen, fifteen, sixteen, or seventeen vectors,wherein the vectors comprise one or more nucleic acids of the invention(e.g., a canine pol I regulatory sequence of the invention) operablylinked to viral cDNA, e.g, influenza viral cDNA.

In certain embodiments, one, two, three, four, five, six, seven, eight,nine, ten, eleven, twelve, or more than twelve of the vectors of theinvention are present in a single plasmid. In certain embodiments, atleast one, two, three, four, five, six, seven, eight, nine, ten, eleven,or twelve of the vectors are present in a separate plasmid. In certainembodiments, each vector is on a separate plasmid.

In certain embodiments, the vectors of the invention are bi-directionalexpression vectors. A bi-directional expression vector of the inventiontypically includes a first promoter and a second promoter, wherein thefirst and second promoters are operably linked to alternative strands ofthe same double stranded cDNA encoding the viral nucleic acid includinga segment of the influenza virus genome. Generally, at least one ofthese promoters is a canine RNA pol I promoter. Optionally, thebi-directional expression vector can include a polyadenylation signaland/or a termination sequence. For example, the polyadenylation signaland/or the termination sequence can be located flanking a segment of theinfluenza virus genome internal to the two promoters. One favorablepolyadenylation signal is a SV40 polyadenylation signal.

In one embodiment, the invention comprises a bidirectional plasmid-basedexpression system and a unidirectional plasmid-based expression system,wherein viral cDNA is inserted between a canine pol I regulatorysequence (e.g., a pol I promoter) of the invention and terminationsequences (inner transcription unit). This inner transcription unit isflanked by an RNA polymerase II (pol II) promoter and a polyadenylationsite (outer transcription unit). In the unidirectional system, the pol Iand pol II promoters are upstream of the cDNA and produce positive-senseuncapped cRNA (from the pol I promoter) and positive-sense capped mRNA(from the pol II promoter). The pol I promoter, pol I terminationsequence, pol II promoter and polyadenylation signal in theunidirectional system may be referred to as comprising an“upstream-to-downstream orientation”. In the bidirectional system, thepol I and pol II promoters are on opposite sides of the cDNA wherein anupstream pol II promoter produces positive-sense capped mRNA and adownstream pol I promoter produces negative-sense uncapped viral RNA(vRNA). These pol I-pol II systems start with the initiation oftranscription of the two cellular RNA polymerase enzymes from their ownpromoters, presumably in different compartments of the nucleus. The polI promoter and pol I termination sequence in the bidirectional systemmay be referred to as comprising a “downstream-to-upstream orientation”whereas the pol II promoter and polyadenylation signal in thebidirectional system may be referred to as comprising an“upstream-to-downstream orientation.”

In other aspects, the invention disclosed herein includes compositionscomprising an expression vector that comprises a polynucleotide sequencetranscribable by canine RNA polymerase I. In certain embodiments, thepolynucleotide produces an influenza vRNA or cRNA. In certainembodiments, the composition comprises a plurality of expression vectorsthat each comprises a polynucleotide sequence transcribable by canineRNA polymerase I. In certain embodiments, the polynucleotides produce aplurality of influenza vRNAs or cRNAs. In certain embodiments, thepolynucleotides produce all eight influenza vRNAs or cRNAs

In other aspects, the invention disclosed herein includes compositionscomprising a plurality of expression vectors of the invention that, whenintroduced into a canine cell in the absence/presence of a helper virus,results in production of an influenza genome.

In certain embodiments, the compositions of the invention comprises aplurality of expression vectors that, when introduced into a canine cellin the absence/presence of a helper virus, results in production of aninfectious influenza virus. In certain embodiments, the infectiousinfluenza virus is a cold-sensitive influenza virus. In certainembodiments, the infectious influenza virus is an attenuated influenzavirus. In certain embodiments, the infectious influenza virus is atemperature sensitive influenza virus. In certain embodiments, theinfectious influenza virus is a cold-adapted influenza virus. In certainembodiments, the infectious influenza virus is an attenuated,temperature sensitive, cold-adapted influenza virus.

In certain embodiments, compositions of the invention comprise a vectorcomprising, from 5′ to 3′, a promoter operably linked to 5′ non-codinginfluenza virus sequences linked to cDNA linked to 3′ non-codinginfluenza virus sequences linked to a transcription terminationsequence. In certain embodiments, one or more of the cDNAs in thevectors is in the sense orientation. In certain embodiments, one or moreof the cDNAs in the vectors is in the anti-sense orientation.

In certain embodiments, the invention provides compositions whichcomprise a plurality of vectors, wherein the plurality of vectorscomprise a vector comprising a canine regulatory sequence operablylinked to an influenza virus polymerase acidic protein (PA) cDNA linkedto a transcription termination sequence, a vector comprising a canineregulatory sequence operably linked to an influenza virus polymerasebasic protein 1 (PB 1) cDNA linked to a transcription terminationsequence, a vector comprising a canine regulatory sequence operablylinked to an influenza virus polymerase basic protein 2 (PB2) cDNAlinked to a transcription termination sequence, a vector comprising acanine regulatory sequence operably linked to an influenza virushemagglutinin (HA) cDNA linked to a transcription termination sequence,a vector comprising a canine regulatory sequence operably linked to aninfluenza virus nucleoprotein (NP) cDNA linked to a transcriptiontermination sequence, a vector comprising a canine regulatory sequenceoperably linked to an influenza virus neuraminidase (NA) cDNA linked toa transcription termination sequence, a vector comprising a canineregulatory sequence operably linked to an influenza virus matrix proteincDNA linked to a transcription termination sequence, and a vectorcomprising a canine regulatory sequence operably linked to an influenzavirus NS cDNA linked to a transcription termination sequence. In certainembodiments, the composition further comprises one or more expressionvectors that express an mRNA encoding one or more influenza polypeptideselected from the group consisting of: PB2, PB1, PA, HA, NP, NA, matrixprotein 1 (M1), matrix protein 2 (M2), and non-structural proteins 1 and2 (NS 1 and NS2). In one embodiment, the composition, when introducedinto a canine cell, results in the production of infectious influenzavirus. In certain embodiments, the infectious influenza virus is acold-sensitive influenza virus. In certain embodiments, the infectiousinfluenza virus is an attenuated influenza virus. In certainembodiments, the infectious influenza virus is a temperature sensitiveinfluenza virus. In certain embodiments, the infectious influenza virusis a cold-adapted influenza virus. In certain embodiments, theinfectious influenza virus is an attenuated, temperature sensitive,cold-adapted influenza virus.

In certain embodiments, the invention provides a composition whichgenerates infectious influenza viruses from cloned viral cDNA,comprising a set of plasmids wherein each plasmid comprises cDNAencoding at least one viral genomic segment, and wherein viral cDNAcorresponding to the viral genomic segment is inserted between a canineRNA polymerase I regulatory sequence of the invention and a regulatoryelement (e.g., a canine pol I termination sequence) for the synthesis ofvRNA or cRNA with an exact 3′ end, which results in expression of vRNAor cRNA.

In certain embodiments, the invention provides a composition whichgenerates infectious influenza viruses from cloned viral cDNA,comprising a set of plasmids wherein each plasmid comprises cDNAencoding at least one viral genomic segment, and wherein viral cDNAcorresponding to the viral genomic segment is inserted between a canineRNA polymerase I regulatory sequence of the invention and a regulatoryelement (e.g., a canine pol I termination sequence) for the synthesis ofvRNA or cRNA with an exact 3′ end, which results in expression of vRNAor cRNA, wherein the canine RNA polymerase I regulatory sequence, viralcDNA, and a regulatory element for the synthesis of vRNA or cRNA with anexact 3′ end are in turn inserted between an RNA polymerase II (pol II)promoter and a polyadenylation signal, which results in expression ofviral mRNA and a corresponding viral protein, wherein the expression ofthe full set of vRNAs or cRNAs and viral proteins results in assembly ofan infectious influenza virus.

In certain embodiments, the regulatory element for the synthesis of vRNAor cRNA with an exact 3′ end is an RNA polymerase I (pol I) terminationsequence. As one skilled in the art is aware, efficient replication andtranscription of influenza vRNA requires very specific sequences at the5′ and 3′ ends of the vRNA. The skilled artisan can use a RNA polymeraseI (pol I) termination sequence to ensure that the sequence of the 3′ endof the RNA transcript made is defined to be the exact end desired forefficient replication and/or transcription of this genomic RNA. Incertain embodiments, the regulatory element for the synthesis of vRNA orcRNA with an exact 3′ end is a ribozyme sequence. In certainembodiments, the pol I promoter is proximal to the polyadenylationsignal and the pol I termination sequence is proximal to the pol IIpromoter. In certain embodiments, the pol I promoter is proximal to thepol II promoter and the pol I termination sequence is proximal to thepolyadenylation signal. In certain embodiments, the influenza virus isan influenza A virus. In certain embodiments, the influenza virus is aninfluenza B virus.

In another aspect, the invention provide a method for producing aninfluenza genomic RNA, comprising transcribing a nucleic acid of theinvention, thereby producing an influenza genomic RNA. In certainembodiments, the influenza genomic RNA is transcribed in a cell-freesystem. In certain embodiments, the influenza genomic RNA is transcribedin a canine cell, e.g., an MDCK cell.

In one embodiment, the methods comprise comprising transcribing aplurality of nucleic acids of the invention, thereby producing aplurality of RNA molecules, e.g., a plurality of influenza genomic RNAs.In certain embodiments, one, two, three, four, five, six, seven, oreight influenza genomic RNAs are transcribed. In certain embodiments, acomplete set of influenza genomic RNAs is transcribed. In certainembodiments, the influenza genomic RNA, when transcribed in a caninecell, e.g., an MDCK cell, in the presence of PA, PB1, PB2, and NP,expresses an influenza protein. In certain embodiments, the influenzaprotein is selected from the group consisting of PB2, PB 1, PA, HA, NP,NA, M1, M2, NS 1, and NS2. In certain embodiments, the complete set ofinfluenza genomic RNAs, when transcribed in a canine cell, e.g., an MDCKcell, in the presence of PA, PB1, PB2, and NP, express an infectiousinfluenza virus. In certain embodiments, the methods compriseintroducing PA, PB1, PB2, and NP together with influenza genomic RNAs.In certain embodiments, PA, PB1, PB2, and NP are provided by a helpervirus. In certain embodiments, the complete set of influenza genomicRNAs is from a cold-adapted, temperature-sensitive, attenuated influenzavirus.

In one embodiment, a method of transcribing a vRNA segment of aninfluenza virus is provided, said method comprising the steps of 1)contacting a polynucleotide comprising a nucleic acid (or activefragment thereof) selected from the group consisting of: SEQ ID Nos 1-19with one or more influenza proteins PB1, PB2, NP, and PA, wherein saidnucleic acid is operably linked to a cDNA molecule encoding said vRNAsegment; and 2) isolating a transcribed vRNA segment. In one specificembodiment, helper virus is used in the method.

In one aspect, the invention provides a method of producing recombinantinfectious recombinant viruses comprising a segmented RNA genome (e.g.,an infectious influenza virus), comprising the steps of culturing caninehost cells, e.g., MDCK cells, comprising one or more expression vectorsof the invention that comprise viral cDNA corresponding to each gene inthe viral genome and one or more expression vectors that express viralmRNA that encodes one or more viral polypeptides; and isolating aninfectious virus population. In one embodiment, the infectious viruspopulation is an influenza virus population. In one embodiment, themethod further comprises the step of introducing the one or moreexpression vectors into the canine host cells prior to said step ofculturing. In one embodiment, the method further comprises the step ofmaking the one or more expression vectors prior to said step ofintroducing.

In one embodiment, a method of producing recombinant infectiousrecombinant viruses comprising a segmented RNA genome (e.g., aninfectious influenza virus) is provided wherein the method comprises thesteps of: a) inserting into one or more expression vectors of theinvention viral cDNA corresponding to each gene in the viral genome; (b)introducing (e.g., by electroporation) said expression vectors and oneor more expression vectors that express viral mRNA that encodes one ormore viral polypeptides into a host cell (e.g., a canine cell) or apopulation of host cells; (c) incubating said host cells; and d),isolating an infectious virus population. In one embodiment, theinfectious recombinant virus is influenza. In certain embodiments, theinfluenza virus is a cold-adapted, temperature-sensitive, attenuatedinfluenza virus.

In one embodiment, a method of producing an infectious recombinant viruscomprising a segmented RNA genome (e.g., an infectious influenza virus)is provided wherein the method comprises the steps of: a) inserting intoone or more expression vectors of the invention a viral cDNAcorresponding to each gene in the viral genome; (b) introducing (e.g.,by electroporation) said expression vectors into a host cell (e.g., acanine cell) or a population of host cells; (c) incubating said hostcells; and d), isolating an infectious virus population. In oneembodiment, the infectious recombinant virus is influenza. In certainembodiments, the influenza virus is a cold-adapted,temperature-sensitive, attenuated influenza virus.

In one embodiment, the present invention provides for methods ofgenerating infectious recombinant influenza virus in host cells usingexpression vectors of the invention to express the vRNA segments orcorresponding cRNAs and influenza virus proteins, in particular PB1,PB2, PA and NA. In accordance with this embodiment, helper virus may ormay not be used to generate the infectious recombinant influenzaviruses.

In another embodiment, the invention provides a method for producing arecombinant influenza virus, comprising culturing canine cellscomprising a plurality of nucleic acids comprising a canine RNApolymerase I regulatory sequence operably linked to one or more cDNAsencoding each influenza genomic RNA and one or more expression vectorsthat express viral mRNA that encodes one or more influenza polypeptides:PB2, PB1, PA, HA, NP, NA, M1, M2, NS1 and NS2; and isolating saidrecombinant influenza virus from the cells.

In certain embodiments, the methods comprise introducing into caninecells expression vectors which direct the expression in the cells ofgenomic or antigenomic viral RNA segments, a nucleoprotein, and anRNA-dependent polymerase, so that ribonucleoprotein complexes can beformed and viral particles can be assembled in the absence of helpervirus; and (b) culturing the cells wherein viral particles are packagedand rescued. In certain embodiments, the recombinant negative strandvirus is a non-segmented virus. In certain embodiments, the recombinantnegative strand RNA virus is a segmented virus. In certain embodiments,the negative strand RNA virus is an influenza virus.

In certain embodiments, the methods comprise introducing into culturedcanine cells expression vectors which direct the expression of thegenomic or antigenomic RNA segments of a segmented negative strand RNAvirus, a nucleoprotein, and an RNA dependent polymerase under conditionspermitting formation of RNP complexes containing the genomic RNAsegments of the virus and assembly of viral particles in the absence ofhelper virus; and culturing the cells wherein the viral particles areproduced. In certain embodiments, the expression vectors directexpression of genomic RNA segments of the virus.

In certain embodiments, the canine cells used in the methods of theinvention comprise one or more expression vectors that express one ormore proteins selected from the nucleoprotein and the subunits of theRNA-dependent RNA polymerase. In certain embodiments, the expressionvectors direct expression of one or more of the nucleoprotein and thesubunits of said RNA-dependent RNA polymerase. In certain embodiments,the expression of the one or more viral proteins from the expressionvectors is under the control of a regulatory sequence selected from theadenovirus 2 major late promoter linked to the spliced tripartite leadersequence of human adenovirus type 2 or the human cytomegalovirusimmediate-early promoter, or a functional derivative of the regulatorysequence.

In certain embodiments, the virus is an influenza virus of type A, B orC. In certain embodiments, the virus is a reassortant virus having vRNAsegments derived from more than one parent virus.

In certain embodiments, the methods of the invention compriseintroducing a plurality of vectors of the invention, each of whichincorporates a portion of an influenza virus into a population of hostcells capable of supporting viral replication. The host cells can becultured under conditions permissive for viral growth, and influenzaviruses can be recovered. In some embodiments, the influenza viruses areattenuated viruses, cold adapted viruses and/or temperature sensitiveviruses. For example, in certain embodiments, the vector-derivedrecombinant influenza viruses can be attenuated, cold adapted,temperature sensitive viruses, such as are suitable for administrationas a live attenuated vaccine, e.g., in a intranasal vaccine formulation.In an exemplary embodiment, the viruses are produced by introducing aplurality of vectors incorporating all or part of an influenza B/AnnArbor/1/66 virus genome, e.g., a ca B/Ann Arbor/1/66 virus genome.

In some embodiments, a plurality of vectors comprising cDNA encoding atleast the 6 internal genome segments (e.g., genome segments encoding allinfluenza proteins except for HA and NA) of one influenza strain andcDNA encoding one or more genome segments (e.g., HA and NA vRNAsegments) of a different influenza strain can be introduced into apopulation of host cells. For example, at least the 6 internal genomesegments (“the backbone”) of a selected attenuated, cold adapted and/ortemperature sensitive influenza A or B strain, e.g., a ca, att, tsstrain of B/Ann Arbor/1/66 or an artificially engineered ca, att, tsinfluenza A or B strain, can be introduced into a population of hostcells along with one or more segments encoding immunogenic antigensderived from another virus strain. Typically the immunogenic surfaceantigens include either or both of the hemagglutinin (HA) and/orneuraminidase (NA) antigens. In embodiments where a single segmentencoding an immunogenic surface antigen is introduced, the 7complementary segments of the selected virus are also introduced intothe host cells.

In certain embodiments, the expression vectors are transfected into thecells by electroporation. In certain embodiments, the expression vectorsare introduced into cells by transfection into cells in the presence ofa liposomal transfection reagent or by means of calcium phosphateprecipitation. In certain embodiments, the expression vectors areplasmids. In certain embodiments, the expression vectors comprise aseparate expression vector for expression of each genomic RNA segment ofsaid virus or the corresponding coding RNAs. In certain embodiments, theexpression of each genomic RNA segment or coding RNA is under thecontrol of a promoter sequence derived from a canine Pol I promoter asdescribed herein.

In certain embodiments, a plurality of plasmid vectors incorporatinginfluenza virus genome segments are introduced into a population of hostcells. For example, in certain embodiments, 8 plasmids, each of whichincorporates a different genome segment can be utilized to introduce acomplete influenza genome into the host cells. Alternatively, a greaternumber of plasmids, incorporating smaller genomic subsequences can beemployed.

In another aspect, the present invention provides a method forgenerating in cultured cells infectious viral particles of a segmentednegative-strand RNA virus having greater than 3 genomic vRNA segments,for example an influenza virus such as an influenza A virus, said methodcomprising: (a) introducing into a population of cells capable ofsupporting growth of said virus a first set of expression vectorscapable of expressing in said cells genomic vRNA segments to provide thecomplete genomic vRNA segments of said virus; (b) introducing into saidcells a second set of expression vectors capable of expressing mRNAencoding one or more polypeptides of said virus; and (c) culturing saidcells whereby said viral particles are produced. In certain embodiments,the cells are canine cells. In certain embodiments, the cells are MDCKcells. In certain embodiments, the virus is influenza B virus. Incertain embodiments, the first set of expression vectors is contained in1-8 plasmids. In certain embodiments, the first set of expressionvectors is contained in one plasmid. In certain embodiments, the secondset of expression vectors is contained in 1-8 plasmids. In certainembodiments, the second set of expression vectors is contained in oneplasmid. In certain embodiments, the first, second, or both sets ofexpression vectors are introduced by electroporation. In certainembodiments, the first set of expression vectors encode each vRNAsegment of an influenza virus. In certain embodiments, the second set ofexpression vectors encode the mRNA of one or more influenza polypeptide.In certain embodiments, the first set or second set of expressionvectors (or both sets) comprise a nucleic acid of the invention, forexample, a canine regulatory sequence of the invention (e.g., canine polI). In certain embodiments, the first set or second set of expressionvectors (or both sets) encode a vRNA or mRNA of a second virus. Forinstance, a set of vectors comprises one or more vectors encoding the HAand/or NA mRNA and/or vRNA of a second influenza virus.

The present invention also provides a method for generating in culturedcells infectious viral particles of a segmented negative-strand RNAvirus having greater than 3 genomic vRNA segments, for example aninfluenza virus such as an influenza A virus, said method comprising:(a) introducing into a population of cells capable of supporting growthof said virus a set of expression vectors capable of both expressing insaid cells genomic vRNA segments to provide the complete genomic vRNAsegments of said virus and capable of expressing mRNA encoding one ormore polypeptides of said virus; (b) culturing said cells whereby saidviral particles are produced. In certain embodiments, the cells arecanine cells. In certain embodiments, the cells are MDCK cells. Incertain embodiments, the virus is influenza B virus. In certainembodiments, the set of expression vectors is contained in 1-17plasmids. In certain embodiments, the set of expression vectors iscontained in 1-8 plasmid. In certain embodiments, the set of expressionvectors is contained in 1-3 plasmids. In certain embodiments, the setsof expression vectors are introduced by electroporation. In certainembodiments, the set of expression vectors encode each vRNA segment ofan influenza virus. In certain embodiments, the set of expressionvectors encode the mRNA of one or more influenza polypeptide. In certainembodiments, the set of expression vectors encode each vRNA segment ofan influenza virus and the mRNA of one or more influenza polypeptide. Incertain embodiments, the set of expression vectors comprise a nucleicacid of the invention, for example, a canine regulatory sequence of theinvention (e.g., canine pol I). In certain embodiments, the set ofexpression vectors encode a vRNA or mRNA of a second virus. Forinstance, the set of vectors comprises one or more vectors encoding theHA and/or NA mRNA and/or vRNA of a second influenza virus. In certainembodiments, the first set or second set of expression vectors (or bothsets) encode a vRNA or mRNA of a second virus. For instance, a set ofvectors comprises one or more vectors encoding the HA and/or NA mRNAand/or vRNA of a second influenza virus.

In certain embodiments, the methods further comprise amplifying viralparticles produced by the canine cells by one or more further cellularinfection steps employing cells which are the same or different from thecanine cells. In certain embodiments, the methods further compriseisolating infectious viral particles. In certain embodiments, themethods further comprise a viral attenuation or killing step. In certainembodiments, the methods further comprise incorporating attenuated orkilled viral particles into a vaccine composition.

In one embodiment, methods of producing viruses of the invention resultin virus titers (24 hours, 36, or 48 hours after introducing vectors ofthe invention into host cells) of at least 0.1×10³ PFU/ml, or at least0.5×10³ PFU/ml, or at least 1.0×10³ PFU/ml, or at least 2×10³ PFU/ml, orat least 3×10³ PFU/ml, or at 4×10³ PFU/ml least, or in the range of0.1−1×10³ PFU/ml, or in the range of 1×10³−5×10³ PFU/ml, or greater than5×10³ PFU/ml.

In some embodiments, the influenza viruses correspond to an influenza Bvirus. In some embodiments, the influenza viruses correspond to aninfluenza A virus. In certain embodiments, the methods includerecovering recombinant and/or reassortant influenza viruses capable ofeliciting an immune response upon administration, e.g., intranasaladministration, to a subject. In some embodiments, the viruses areinactivated prior to administration, in other embodiments,live-attenuated viruses are administered. Recombinant and reassortantinfluenza A and influenza B viruses produced according to the methods ofthe invention are also a feature of the invention. In certainembodiments, the viruses include an attenuated influenza virus, a coldadapted influenza virus, a temperature sensitive influenza virus, or avirus with any combination of these desirable properties. In oneembodiment, the influenza virus incorporates an influenza B/AnnArbor/1/66 strain virus, e.g., a cold adapted, temperature sensitive,attenuated strain of B/Ann Arbor/1/66. In another embodiment, theinfluenza virus incorporates an influenza A/Ann Arbor/6/60 strain virus,e.g., a cold adapted, temperature sensitive, attenuated strain of A/AnnArbor/6/60.

Optionally, reassortant viruses are produced by introducing vectorsencoding the six internal vRNAs of a viral strain selected for itsfavorable properties regarding vaccine production, in combination withvectors encoding vRNA segments of the surface antigens (HA and NA) of aselected, e.g., pathogenic strain. For example, the HA segment can befavorably selected from a pathogenically relevant H1, H3 or B strain, asis routinely performed for vaccine production. Similarly, the HA segmentcan be selected from an emerging pathogenic strain such as an H2 strain(e.g., H2N2), an H5 strain (e.g., H5N1) or an H7 strain (e.g., H7N7).Alternatively, the seven complementary gene segments of the first strainare introduced in combination with either the HA or NA encoding segment.In certain embodiments, the internal gene segments are derived from theinfluenza B/Ann Arbor/1/66 or the A/Ann Arbor/6/60 strain. In addition,an influenza virus may be produced (e.g., an H5N1, H9N2, H7N7, or HxNy(where x=1-9 and y=1-15) that comprises a modified HA gene. For example,the HA gene may be modified by removal of the polybasic cleavage site.

In another aspect, the invention provides a host cell comprising anucleic acid or expression vector of the invention. In certainembodiments, the cell is a canine cell. In certain embodiments, thecanine cell is a kidney cell. In certain embodiments, the canine kidneycell is an MDCK cell. In other embodiments, the cell is selected fromthe group consisting of Vero cells, Per.C6 cells, BHK cells, PCK cells,MDCK cells, MDBK cells, 293 cells (e.g., 293T cells), and COS cells. Insome embodiments, co-cultures of a mixture of at least two of these celllines, e.g., a combination of COS and MDCK cells or a combination of293T and MDCK cells, constitute the population of host cells.

The host cells comprising the influenza vectors of the invention can begrown in culture under conditions permissive for replication andassembly of viruses. Typically, host cells incorporating the influenzaplasmids can be cultured at a temperature below 37° C., preferably at atemperature equal to, or less than, 35° C. In certain embodiments, thecells are cultured at a temperature between 32° C. and 35° C. In someembodiments, the cells are cultured at a temperature between about 32°C. and 34° C., e.g., at about 33° C. Following culture for a suitableperiod of time to permit replication of the virus to particular titer,recombinant viruses can be recovered. Optionally, the recovered virusescan be inactivated.

In yet another aspect, the invention provides a method for engineeringan influenza virus such that its growth is restricted to particular celltypes including, but not limited to, MRC-5, WI-38, FRhL-2, PerC6, 293,NIH 3T3, CEF, CEK, DF-1, Vero, MDCK, Mv1Lu, human epithelial cells andSF9 cell types. In one embodiment, growth is restricted such that aninfluenza virus can not grow in a human primary cell (e.g., PerC6). Inanother embodiment, growth is restricted such that an influenza viruscan not grow in an human epithelial cell. One skilled in the art willrecognize that the growth restriction phenotype may be combined with oneor more additional phenotypes such as cold adapted, temperaturesensitive, attenuated, etc. It will also be recognized that a mutationresponsible for a growth restricted phenotype may also contribute and/orbe responsible for additional phenotypes such as those listed above.

In another aspect, the invention provides novel methods for rescuingrecombinant or reassortant influenza A or influenza B viruses (i.e.,wild type and variant strains of influenza A and/or influenza viruses)from MDCK cells in culture. In certain embodiments, a plurality ofvectors incorporating an influenza virus genome whose transcription iscontrolled by a canine regulatory sequence of the invention iselectroporated into a population of MDCK cells. The cells can be grownunder conditions permissive for viral replication, e.g., in the case ofcold adapted, attenuated, temperature sensitive virus strains, the MDCKcells are grown at a temperature below 37° C., preferably at atemperature equal to, or less than, 35° C. Typically, the cells arecultured at a temperature between 32° C. and 35° C. In some embodiments,the cells are cultured at a temperature between about 32° C. and 34° C.,e.g., at about 33° C. Optionally (e.g., for vaccine production), theMDCK cells are grown in serum free medium without any animal-derivedproducts.

In some embodiments of the methods described above, influenza virusescan be recovered following culture of the host cells incorporating theinfluenza genome plasmids. In some embodiments, the recovered virusesare recombinant viruses. In some embodiments, the viruses arereassortant influenza viruses having genetic contributions from morethan one parental strain of virus. Optionally, the recovered recombinantor reassortant viruses are further amplified by passage in culturedcells or in hens' eggs.

Optionally, the recovered viruses can be inactivated. In someembodiments, the recovered viruses comprise an influenza vaccine. Forexample, the recovered influenza vaccine can be a reassortant influenzaviruses (e.g., 6:2 or 7:1 reassortant viruses) having an HA and/or NAantigen derived from a selected strain of influenza A or influenza B. Inone embodiment, the HA or NA antigen is modified. In certain favorableembodiments, the reassortant influenza viruses have an attenuatedphenotype. Optionally, the reassortant viruses are cold adapted and/ortemperature sensitive, e.g., an attenuated, cold adapted or temperaturesensitive influenza A or B virus. Such influenza viruses are useful, forexample, as live attenuated vaccines for the prophylactic production ofan immune response specific for a selected, e.g., pathogenic influenzastrain. Influenza viruses, e.g., attenuated reassortant viruses,produced according to the methods of the invention are an additionalfeature of the invention.

In another aspect, the invention relates to methods for producing arecombinant influenza virus vaccine comprising introducing a pluralityof vectors incorporating an influenza virus genome whose transcriptionis controlled by a canine regulatory sequence of the invention (e.g., acanine RNA pol I promoter) into a population of host cells capable ofsupporting replication of influenza virus, culturing the host cells at atemperature less than or equal to 35° C., and recovering an influenzavirus capable of eliciting an immune response upon administration to asubject. The vaccines can comprise either influenza A or influenza Bstrain viruses.

In some embodiments, the influenza vaccine viruses include an attenuatedinfluenza virus, a cold adapted influenza virus, or a temperaturesensitive influenza virus. In certain embodiments, the viruses possess acombination of these desirable properties. In an embodiment, theinfluenza virus contains an influenza A/Ann Arbor/6/60 strain virus. Inanother embodiment, the influenza virus incorporates an influenza B/AnnArbor/1/66 strain virus. Alternatively, the vaccine includesartificially engineered influenza A or influenza B viruses incorporatingat least one substituted amino acid which influences the characteristicbiological properties of ca A/Ann Arbor/6/60 or ca/B/Ann Arbor/1/66,such as a unique amino acid of these strains.

In one embodiment, a vaccine comprising a population of recombinantviruses (or viruses derived therefrom) produced by the methods of theinvention is provided. In a specific embodiment, the vaccine comprises alive virus produced by the methods. In another specific embodiment, thevaccine comprises a killed or inactivated virus produced by the methods.In another specific embodiment, the vaccine comprises an immunogeniccomposition prepared from a live, killed or inactivated virus producedby the methods. In another specific embodiment, the vaccine comprises animmunogenic composition prepared from a live attenuated, cold adapted,temperature-sensitive influenza virus produced by the method. In anotherspecific embodiment, the vaccine comprises a live attenuated, coldadapted, temperature-sensitive influenza virus produced by the method ora virus derived therefrom.

5. BRIEF DESCRIPTION OF THE FIGS.

FIG. 1 presents growth curves of wt and ca B strain (B/Beijing/243/97)in both PerC6 and MDCK cells; virus titer for each time point wasdetermined by TCID50 assay.

FIG. 2 presents growth curves of wt and ca A strains (A/Sydney/05/97 andA/Beijing/262/95) in both PerC6 and MDCK cells; virus titer for eachtime point was determined by TCID50 assay.

FIG. 3 presents growth curves of wt and ca A strain (A/Ann Arbor/6/60)in both PerC6 and MDCK cells; virus titer for each time point wasdetermined by TCID50 assay.

FIG. 4 presents real time analysis of viral RNA of A/Sydney in PerC6 andMDCK cells, using Taqmang (Roche Molecular Systems; Palo Alto, Calif.)probes specific for the M segment of the viral RNA.

FIG. 5 presents growth curves of ca A/Vietnam/1203/2004 (H5N1) in MDCKcells; virus titer for each time point was determined by TCID50 assay.

FIG. 6 presents a diagram showing rescue of each influenza gene segmentas a 7:1 reassortant generated by the eight-plasmid rescue technique.

FIG. 7 presents growth curves of each of the 7:1 reassortants in PerC6cells; virus titer for each time point was determined by TCID50 assay.

FIG. 8 presents a restriction map of an Eco RI fragment that comprises acanine RNA pol I regulatory sequence.

FIGS. 9A, 9B and 9C presents the nucleotide sequence (SEQ ID NO: 1) ofan approximately 3.5 kB nucleic acid cloned from canine genomic DNA,which encodes at least a portion of the 18s rRNA gene, beginning atnucleotide 1804 in the sequence presented.

FIG. 10 presents a map of plasmid pAD3000, which can be readily adaptedto make an expression vector of the invention.

FIG. 11 presents a diagram of the MDCK pol I promoter constructs used inthe mini-genome assay.

FIG. 12 presents the results of a mini-genome assay. The EGFP signalgenerated from the −1, +1 and +2 MDCK pol I promoter constructs areshown in the top left, middle and right panels, respectively. A minuspromoter control shows only background fluorescence (bottom left). As apositive control cells were also transfected with a CMV-EGFP construct(bottom right).

6. DETAILED DESCRIPTION OF THE INVENTION

Plasmid rescue of influenza virus generally comprises introduction ofexpression vectors for expressing viral proteins and transcribing viralgenomic RNA into suitable host cells. Transcription of the viral genomicRNA is generally performed with an RNA polymerase I enzyme, as theseenzymes produce transcripts with ends suitable for use as viral genomes.Thus, RNA pol I promoters and other regulatory elements are used toinitiate transcription of genomic RNAs during plasmid rescue.Unfortunately, RNA pol I promoters are highly species-specific. That is,RNA pol I from one species may or may not bind efficiently to an RNA polI promoter from an unrelated species. Accordingly, the availability ofRNA pol I promoters limits the cells in which plasmid rescue can beperformed. Prior to the present invention, plasmid rescue was notpossible in canine cells. For the first time, plasmid rescue in caninecells is possible based on the disclosure of the present invention asfollows.

Accordingly, in a first aspect, isolated nucleic acids of the inventioncomprising a canine RNA polymerase I regulatory sequences are provided.In certain embodiments, the regulatory sequence is a promoter. In oneembodiment, the regulatory sequence is a canine pol I promoter sequence.In another embodiment, the regulatory sequence is operably linked tocloned viral cDNA. In yet another embodiment, the cloned viral cDNAencodes viral RNA of a negative or positive strand virus or thecorresponding cRNA. In one specific embodiment, the cloned viral cDNAencodes genomic viral RNA (or the corresponding cRNA) of an influenzavirus.

In one specific embodiment, isolated nucleic acids of the inventioncomprise a canine RNA polymerase I regulatory sequence and atranscriptional termination sequence. In certain embodiments,transcriptional termination sequences is a pol I termination sequence.In certain embodiments, transcriptional termination sequences is ahuman, monkey, or canine pol I termination sequence.

In certain embodiments, nucleic acids of the invention comprise apolynucleotide sequence or a functionally active fragment thereof, e.g.,a canine RNA pol I regulatory sequence, that binds a human, primate,mouse or canine pol I polypeptide and is at least 100% or about 99%,98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, or 65% identical to one ormore nucleotide sequences selected from the group consisting of: SEQ IDNos: 1-19. In one embodiment, the polynucleotide sequence orfunctionally active fragment thereof further retains the ability toinitiate transcription, in the presence of appropriate polypeptides(e.g., human, primate, mouse or canine pol I polypeptides), of a secondpolynucleotide sequence operatively linked to the nucleotide sequence.In one embodiment, “functionally active fragments” of the nucleic acidsset forth in SEQ ID Nos: 1-19 retain one or more functional activitiesdescribed herein of the full length sequences of SEQ ID Nos: 1-19. Forinstance, functionally active fragments of the regulatory sequence setforth as SEQ ID NO: 1 are provided whereby the regulatory sequencefragment is operably linked to a nucleic acid to be transcribed and, inthe presence of suitable proteins in vitro or in vivo, is transcribed.

In certain embodiments, nucleic acids of the invention comprise apolynucleotide sequence or a fragment thereof, e.g., a canine RNA pol Iregulatory sequence, that binds a human, primate, mouse or canine pol Ipolypeptide and/or is 100% or at least or about 99%, 98%, 97%, 96%, 95%,90%, 85%, 80%, 75%, 70%, or 65% identical to one or more nucleotidesequences selected from the group consisting of: SEQ ID Nos: 1-19. Inone embodiment, the polynucleotide sequence or fragment thereof furtherretains the ability to initiate transcription, in the presence ofappropriate polypeptides (e.g., human, primate, mouse or canine pol Ipolypeptides), of a second polynucleotide sequence operatively linked tothe nucleotide sequence.

In certain aspects, the present invention provides an isolated nucleicacid that comprises a canine RNA pol I promoter. Preferably, the canineRNA pol I promoter is operably linked to a nucleic acid to betranscribed, such as, e.g., an influenza genomic RNA. Introduction ofthe nucleic acid into a canine cell results in transcription of theinfluenza genomic RNA, and, in the presence of suitable influenzaproteins, the RNA transcript can be packed into an infectious influenzavirus. In one embodiment, isolated nucleic acids are provided whichcomprise a canine RNA regulatory sequence of the invention (e.g., acanine RNA pol I promoter), wherein the regulatory sequence is operablylinked to a nucleic acid to be transcribed and, in the presence ofsuitable proteins in vitro or in vivo, is transcribed. In oneembodiment, the nucleic acid operably linked to said regulatory sequenceis an influenza vRNA segment.

In another aspect, the invention provides vectors and methods forproducing recombinant influenza viruses in canine cell culture entirelyfrom cloned viral DNA. For example, influenza viruses can be produced byintroducing a plurality of vectors comprising cloned cDNA encoding eachviral genome segment under the transcriptional control of a canine RNAregulatory sequence (e.g., a canine pol I promoter) of the inventioninto canine host cells, culturing the canine cells, and isolating therecombinant influenza viruses produced from the cell culture. Whenvectors encoding an influenza virus genome are thus introduced (e.g., byelectroporation) into canine cells, recombinant viruses suitable asvaccines can be recovered by standard purification procedures. Using thevector system and methods of the invention, reassortant virusesincorporating the six internal gene segments of a strain selected forits desirable properties with respect to vaccine production, and theimmunogenic HA and NA segments from a selected, e.g., pathogenic strain,can be rapidly and efficiently produced in tissue culture. Thus, thesystem and methods described herein are useful for the rapid productionin canine cell culture of recombinant and reassortant influenza A and Bviruses, including viruses suitable for use as vaccines, including liveattenuated vaccines. Vaccines prepared according to methods of theinvention may be delivered intranasally or intramuscularly.

Typically, a single Master Donor Virus (MDV) strain is selected for eachof the A and B subtypes. In the case of a live attenuated vaccine, theMaster Donor Virus strain is typically chosen for its favorableproperties, e.g., temperature sensitivity, cold adaptation and/orattenuation, relative to vaccine production. For example, exemplaryMaster Donor Strains include such temperature sensitive, attenuated andcold adapted strains of A/Ann Arbor/6/60 and B/Ann Arbor/1/66,respectively.

For example, a selected master donor type A virus (MDV-A), or masterdonor type B virus (MDV-B), can be produced from a plurality of clonedviral cDNAs constituting the viral genome. In an exemplary embodiment,recombinant viruses are produced from eight cloned viral cDNAs. Eightviral cDNAs representing either the selected MDV-A or MDV-B sequences ofPB2, PB 1, PA, NP, HA, NA, M and NS are cloned into an expressionvector, e.g., a bi-directional expression vector such as a plasmid(e.g., pAD3000), such that the viral genomic RNA can be transcribed froma canine RNA polymerase I (pol I) promoter from one strand and the viralmRNAs can be synthesized from an RNA polymerase II (pol II) promoterfrom the other strand. Optionally, any gene segment can be modified,including the HA segment (e.g., to remove the multi-basic cleavagesite).

Infectious recombinant MDV-A or MDV-B virus is then recovered followingtransfection of plasmids bearing the eight viral cDNAs into appropriatehost cells, e.g., MDCK cells. Using the plasmids and methods describedherein, the invention is useful, e.g., for generating 6:2 reassortantinfluenza vaccines by co-transfection of the 6 internal genes (PB 1,PB2, PA, NP, M and NS) of the selected virus (e.g., MDV-A, MDV-B, PR8)together with the HA and NA derived from different corresponding type (Aor B) influenza viruses. For example, the HA segment is favorablyselected from a pathogenically relevant H1, H3 or B strain, as isroutinely performed for vaccine production. Similarly, the HA segmentcan be selected from a strain with emerging relevance as a pathogenicstrain such as an H2 strain (e.g., H2N2), an H5 strain (e.g., H5N1) oran H7 strain (e.g., H7N7). Reassortants incorporating seven genomesegments of the MDV and either the HA or NA gene of a selected strain(7:1 reassortants) can also be produced. In addition, this system isuseful for determining the molecular basis of phenotypiccharacteristics, e.g., the attenuated (att), cold adapted (ca), andtemperature sensitive (ts) phenotypes, relevant to vaccine production.

6.1 DEFINITIONS

Unless defined otherwise, all scientific and technical terms areunderstood to have the same meaning as commonly used in the art to whichthey pertain. For the purpose of the present invention the followingterms are defined below.

The terms “nucleic acid,” “polynucleotide,” “polynucleotide sequence”and “nucleic acid sequence” refer to single-stranded or double-strandeddeoxyribonucleotide or ribonucleotide polymers, or chimeras or analoguesthereof. As used herein, the term optionally includes polymers ofanalogs of naturally occurring nucleotides having the essential natureof natural nucleotides in that they hybridize to single-stranded nucleicacids in a manner similar to naturally occurring nucleotides (e.g.,peptide nucleic acids). Unless otherwise indicated, a particular nucleicacid sequence of this invention encompasses complementary sequences, inaddition to the sequence explicitly indicated.

The term “gene” is used broadly to refer to any nucleic acid associatedwith a biological function. Thus, genes include coding sequences and/orthe regulatory sequences required for their expression. The term “gene”applies to a specific genomic sequence, as well as to a cDNA or an mRNAencoded by that genomic sequence.

Genes also include non-expressed nucleic acid segments that, forexample, form recognition sequences for other proteins. Non-expressedregulatory sequences include “promoters” and “enhancers,” to whichregulatory proteins such as transcription factors bind, resulting intranscription of adjacent or nearby sequences. A “Tissue specific”promoter or enhancer is one which regulates transcription in a specifictissue type or cell type, or types.

A “promoter” or “promoter sequence” is a DNA regulatory region capableof initiating transcription of a nucleic acid sequence to which it isoperably attached, when appropriate transcription-related enzymes, e.g.,RNA polymerase, are present under conditions, e.g., culture orphysiological conditions, whereby the enzymes are functional. A promotercan be present upstream or downstream from the nucleic acid sequencewhose transcription it initiates. A promoter sequence which is locatedupstream of a cDNA is bounded at its 3′ terminus by a transcriptioninitiation site and extends upstream (5′ direction) to include theminimum number of bases or elements necessary to initiate transcriptionat levels detectable above background. A promoter sequence which islocated downstream of a cDNA (to express a (−)RNA) is bounded at its 5′terminus by a transcription initiation site and extends downstream (3′direction) to include the minimum number of bases or elements necessaryto initiate transcription at levels detectable above background. Thebidirectional system of the invention includes both upstream anddownstream promoters; the unidirectional system includes only upstreampromoters. Within or adjacent to the promoter sequence will be found atranscription initiation site (conveniently defined for example, bymapping with nuclease S1), and can also include protein binding domains(consensus sequences) that promote, regulate, enhance, or are otherwiseresponsible for the binding of RNA polymerase.

A “canine RNA polymerase I regulatory sequence” or “canine RNApolymerase I regulatory element” (or functionally active fragmentsthereof), as used herein, refers to a nucleic acid sequence that iscapable of increasing transcription of a nucleic acid sequence to whichit is operably attached, when canine RNA polymerase I and, optionally,associated transcription factors, are present under conditions, e.g.,culture or physiological conditions, whereby the enzymes are functional.Examples of canine RNA polymerase I regulatory sequences include acanine RNA polymerase I promoter, which increases transcription of anucleic acid operably linked thereto above background, and a canine RNApolymerase I enhancer, which increases transcription of a nucleic acidoperably linked to a canine RNA polymerase I promoter above the levelobserved in the absence of a canine RNA polymerase I enhancer. One testfor identifying a canine RNA polymerase I regulatory element is tointroduce the putative canine RNA polymerase I regulatory element,operably linked to a nucleic acid of interest, into a suitable caninecell, e.g., an MDCK cell, and detect transcription of the nucleic acidof interest using a conventional assay, e.g., a Northern blot.Comparison of transcription levels of the nucleic acid in the presenceand absence of the putative canine RNA polymerase I regulatory elementpermits the skilled artisan to determine whether the nucleic acidelement is a canine RNA polymerase I regulatory element.

The term “vector” refers to a nucleic acid, e.g., a plasmid, viralvector, recombinant nucleic acid or cDNA that can be used to introduceheterologous nucleic acid sequences into a cell. A vector of theinvention typically will comprise a regulatory sequence of theinvention. The vectors can be autonomously replicating or notautonomously replicating. A vector can also be a naked RNApolynucleotide, a naked DNA polynucleotide, a polynucleotide composed ofboth DNA and RNA within the same strand, a poly-lysine-conjugated DNA orRNA, a peptide-conjugated DNA or RNA, a liposome-conjugated DNA, or thelike, that are not autonomously replicating. Most commonly, the vectorsof the present invention are plasmids.

An “expression vector” is a vector, such as a plasmid, which is capableof promoting expression, e.g., transcription, of a nucleic acidincorporated therein. An expression vector of the invention typicallywill comprise a regulatory sequence of the invention. The expressionvectors can be autonomously replicating or not autonomously replicating.Typically, the nucleic acid to be expressed is “operably linked” to apromoter and/or enhancer, and is subject to transcription regulatorycontrol by the promoter and/or enhancer.

A “bi-directional expression vector” is typically characterized by twoalternative promoters oriented in the opposite direction relative to anucleic acid situated between the two promoters, such that expressioncan be initiated in both orientations resulting in, e.g., transcriptionof both plus (+) or sense strand, and negative (−) or antisense strandRNAs. Alternatively, the bi-directional expression vector can be anambisense vector, in which the viral mRNA and viral genomic RNA (as acRNA) are expressed from the same strand.

In the context of the invention, the term “isolated” refers to abiological material, such as a nucleic acid or a protein, which issubstantially free from components that normally accompany or interactwith it in its naturally occurring environment. The isolated materialoptionally comprises material not found with the material in its naturalenvironment, e.g., a cell. For example, if the material is in itsnatural environment, such as a cell, the material has been placed at alocation in the cell (e.g., genome or genetic element) not native to amaterial found in that environment. For example, a naturally occurringnucleic acid (e.g., a coding sequence, a promoter, an enhancer, etc.)becomes isolated if it is introduced by non-naturally occurring means toa locus of the genome (e.g., a vector, such as a plasmid or virusvector, or amplicon) not native to that nucleic acid. Such nucleic acidsare also referred to as “heterologous” nucleic acids.

The term “recombinant” indicates that the material (e.g., a nucleic acidor protein) has been artificially or synthetically (non-naturally)altered by human intervention. The alteration can be performed on thematerial within, or removed from, its natural environment or state.Specifically, when referring to a virus, e.g., an influenza virus, thevirus is recombinant when it is produced by the expression of arecombinant nucleic acid.

The term “reassortant,” when referring to a virus, indicates that thevirus includes genetic and/or polypeptide components derived from morethan one parental viral strain or source. For example, a 7:1 reassortantincludes 7 viral genomic segments (or gene segments) derived from afirst parental virus, and a single complementary viral genomic segment,e.g., encoding hemagglutinin or neuraminidase, from a second parentalvirus. A 6:2 reassortant includes 6 genomic segments, most commonly the6 internal genes from a first parental virus, and two complementarysegments, e.g., hemagglutinin and neuraminidase, from a differentparental virus.

The term “introduced” when referring to a heterologous or isolatednucleic acid refers to the incorporation of a nucleic acid into aeukaryotic or prokaryotic cell where the nucleic acid can beincorporated into the genome of the cell (e.g., chromosome, plasmid,plastid or mitochondrial DNA), converted into an autonomous replicon, ortransiently expressed (e.g., transfected mRNA). The term includes suchmethods as “infection,” “transfection,” “transformation” and“transduction.” In the context of the invention a variety of methods canbe employed to introduce nucleic acids into prokaryotic cells, includingelectroporation, calcium phosphate precipitation, lipid mediatedtransfection (lipofection), etc.

The term “host cell” means a cell which can or has taken up a nucleicacid, such as a vector, and supports the replication and/or expressionof the nucleic acid, and optionally production of one or more encodedproducts including a polypeptide and/or a virus. Host cells can beprokaryotic cells such as E. Coli, or eukaryotic cells such as yeast,insect, amphibian, avian or mammalian cells, including human cells.Exemplary host cells in the context of the invention include Vero(African green monkey kidney) cells, Per.C6 cells (human embryonicretinal cells), BHK (baby hamster kidney) cells, primary chick kidney(PCK) cells, Madin-Darby Canine Kidney (MDCK) cells, Madin-Darby BovineKidney (MDBK) cells, 293 cells (e.g., 293T cells), and COS cells (e.g.,COSI, COS7 cells). The term host cell encompasses combinations ormixtures of cells including, e.g., mixed cultures of different celltypes or cell lines (e.g., Vero and CEK cells). A co-cultivation ofelectroporated SF Vero cells is described for example in PCTIUS04/42669filed Dec. 22, 2004, which is incorporated by reference in theirentirety.

The expression “artificially engineered” is used herein to indicate thatthe virus, viral nucleic acid or virally encoded product, e.g., apolypeptide, a vaccine, comprises at least one mutation introduced byrecombinant methods, e.g., site directed mutagenesis, PCR mutagenesis,etc. The expression “artificially engineered” when referring to a virus(or viral component or product) comprising one or more nucleotidemutations and/or amino acid substitutions indicates that the viralgenome or genome segment encoding the virus (or viral component orproduct) is not derived from naturally occurring sources, such as anaturally occurring or previously existing laboratory strain of virusproduced by non-recombinant methods (such as progressive passage at 25°C.), e.g., a wild type or cold adapted A/Ann Arbor/6/60 or B/AnnArbor/l/66strain.

The term “% sequence identity” is used interchangeably herein with theterm “% identity” and refers to the level of amino acid sequenceidentity between two or more peptide sequences or the level ofnucleotide sequence identity between two or more nucleotide sequences,when aligned using a sequence alignment program. For example, as usedherein, 80% identity means the same thing as 80% sequence identitydetermined by a defined algorithm, and means that a given sequence is atleast 80% identical to another length of another sequence. Exemplarylevels of sequence identity include, but are not limited to, 60, 70, 80,85, 90, 95, 98% or more sequence identity to a given sequence.

The term “% sequence homology” is used interchangeably herein with theterm “% homology” and refers to the level of amino acid sequencehomology between two or more peptide sequences or the level ofnucleotide sequence homology between two or more nucleotide sequences,when aligned using a sequence alignment program. For example, as usedherein, 80% homology means the same thing as 80% sequence homologydetermined by a defined algorithm, and accordingly a homologue of agiven sequence has greater than 80% sequence homology over a length ofthe given sequence. Exemplary levels of sequence homology include, butare not limited to, 60, 70, 80, 85, 90, 95, 98% or more sequencehomology to a given sequence.

Exemplary computer programs which can be used to determine identitybetween two sequences include, but are not limited to, the suite ofBLAST programs, e.g., BLASTN, BLASTX, and TBLASTX, BLASTP and TBLASTN,publicly available on the Internet at the NCBI website. See alsoAltschul et al., 1990, J. Mol. Biol. 215:403-10 (with special referenceto the published default setting, i.e., parameters w=4, t=17) andAltschul et al., 1997, Nucleic Acids Res., 25:3389-3402. Sequencesearches are typically carried out using the BLASTP program whenevaluating a given amino acid sequence relative to amino acid sequencesin the GenBank Protein Sequences and other public databases. The BLASTXprogram is preferred for searching nucleic acid sequences that have beentranslated in all reading frames against amino acid sequences in theGenBank Protein Sequences and other public databases. Both BLASTP andBLASTX are run using default parameters of an open gap penalty of 11.0,and an extended gap penalty of 1.0, and utilize the BLOSUM-62 matrix.See id.

A preferred alignment of selected sequences in order to determine “%identity” between two or more sequences, is performed using for example,the CLUSTAL-W program in MacVector version 6.5, operated with defaultparameters, including an open gap penalty of 10.0, an extended gappenalty of 0.1, and a BLOSUM 30 similarity matrix.

“Hybridizing specifically to” or “specific hybridization” or“selectively hybridize to”, refers to the binding, duplexing, orhybridizing of a nucleic acid molecule preferentially to a particularnucleotide sequence under stringent conditions when that sequence ispresent in a complex mixture (e.g., total cellular) DNA or RNA.

The term “stringent conditions” refers to conditions under which a probewill hybridize preferentially to its target subsequence, and to a lesserextent to, or not at all to, other sequences. “Stringent hybridization”and “stringent hybridization wash conditions” in the context of nucleicacid hybridization experiments such as Southern and northernhybridizations are sequence dependent, and are different under differentenvironmental parameters. An extensive guide to the hybridization ofnucleic acids can be found in Tijssen, 1993, Laboratory Techniques inBiochemistry and Molecular Biology—Hybridization with Nucleic AcidProbes, part I, chapter 2, “Overview of principles of hybridization andthe strategy of nucleic acid probe assays”, Elsevier, N.Y.; Sambrook etal., 2001, Molecular Cloning: A Laboratory Manual, Cold Spring HarborLaboratory, 3^(rd) ed., NY; and Ausubel et al., eds., Current Edition,Current Protocols in Molecular Biology, Greene Publishing Associates andWiley Interscience, NY.

Generally, highly stringent hybridization and wash conditions areselected to be about 5° C. lower than the thermal melting point (Tm) forthe specific sequence at a defined ionic strength and pH. The Tm is thetemperature (under defined ionic strength and pH) at which 50% of thetarget sequence hybridizes to a perfectly matched probe. Very stringentconditions are selected to be equal to the Tm for a particular probe.

One example of stringent hybridization conditions for hybridization ofcomplementary nucleic acids which have more than about 100 complementaryresidues on a filter in a Southern or northern blot is 50% formalin with1 mg of heparin at 42° C, with the hybridization being carried outovernight. An example of highly stringent wash conditions is 0.15 M NaClat 72° C. for about 15 minutes. An example of stringent wash conditionsis a 0.2×SSC wash at 65° C. for 15 minutes. See Sambrook et al. for adescription of SSC buffer. A high stringency wash can be preceded by alow stringency wash to remove background probe signal. An exemplarymedium stringency wash for a duplex of, e.g., more than about 100nucleotides, is 1×SSC at 45° C. for 15 minutes. An exemplary lowstringency wash for a duplex of, e.g., more than about 100 nucleotides,is 4-6×SSC at 40° C. for 15 minutes. In general, a signal to noise ratioof 2× (or higher) than that observed for an unrelated probe in theparticular hybridization assay indicates detection of a specifichybridization.

The term “about,” as used herein, unless otherwise indicated, refers toa value that is no more than 10% above or below the value being modifiedby the term. For example, the term “about 5 μg/kg” means a range of from4.5 μg/kg to 5.5 μg/kg. As another example, “about 1 hour” means a rangeof from 48 minutes to 72 minutes.

The term “encode,” as used herein, refers to the property of a nucleicacid, e.g., deoxyribonucleic acid, to transcribe a complementary nucleicacid, including a nucleic acid that can be translated into apolypeptide. For example, a deoxyribonucleic acid can encode an RNA thatis transcribed from the deoxyribonucleic acid. Similarly, thedeoxyribonucleic acid can encode a polypeptide translated from an RNAtranscribed from the deoxyribonucleic acid.

6.2 Nucleic Acids Comprising Canine RNA Pol I Regulatory Elements

In one embodiment, isolated nucleic acids are provided which comprise acanine RNA regulatory sequence of the invention (e.g., a canine RNA polI promoter). The regulatory sequence can, for example, be operablylinked to a nucleic acid to be transcribed and can, in the presence ofsuitable proteins in vitro or in vivo, be transcribed. In oneembodiment, the nucleic acid operably linked to said regulatory sequenceis an influenza vRNA segment.

In certain aspects, the present invention provides an isolated nucleicacid that comprises a canine RNA pol I promoter. Preferably, the canineRNA pol I promoter is operably linked to a nucleic acid to betranscribed, such as, e.g., an influenza genomic RNA. Introduction ofthe nucleic acid into a canine cell can result in transcription of theinfluenza genomic RNA, and, in the presence of suitable influenzaproteins, the RNA transcript or transcripts can be packed into aninfluenza virus, e.g., an infectious influenza virus.

In certain embodiments, nucleic acid acids of the invention comprise acanine RNA pol I regulatory sequence or fragment thereof that binds ahuman, primate, mouse or canine pol I polypeptide and is at least orabout 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%,86%, 85%, 84%, 83%, 82%, 81%, 80% 79%, 78%, 77%, 76%, 75%, 74%, 73%,72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, or 60%identical to one or more nucleotide sequences selected from the groupconsisting of: SEQ ID Nos1-19. In one embodiment, the RNA pol Iregulatory sequence or fragment thereof further retains the ability toinitiate transcription of a gene operatively linked to the nucleotidesequence.

Furthermore, the nucleic acids of the invention also encompassderivative versions of nucleic acids comprising a canine RNA pol Ipromoter. Such derivatives can be made by any method known by one ofskill in the art without limitation from the canine RNA pol I regulatorysequences identified hereinafter. For example, derivatives can be madeby site-specific mutagenesis, including substitution, insertion, ordeletion of one, two, three, five, ten or more nucleotides, of thenucleic acids. Alternatively, derivatives can be made by randommutagenesis. One method for randomly mutagenizing a nucleic acidcomprises amplifying the nucleic acid in a PCR reaction in the presenceof 0.1 mM MnCl₂ and unbalanced nucleotide concentrations. Theseconditions increase the misincorporation rate of the polymerase used inthe PCR reaction and result in random mutagenesis of the amplifiednucleic acid. Preferably, the derivative nucleic acids retain theability to initiate transcription of a gene operatively linked to thenucleotide sequence.

In certain embodiments, embodiments, the nucleic acid of the inventioncomprises at least about 10, 20,30, 40, 50, 60, 70, 80, 90, 100, 110,120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250,260, 270, 280, 290, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550,600, 650, 700, 750, 800, 850, 900, 950, or 1000 consecutive nucleotidesof one or more nucleotide sequences selected from the group consistingof: SEQ ID Nos 1-19. Preferably, the nucleic acid comprises a sequencethat can initiate transcription of a gene operatively linked to thenucleotide sequence in canine cells, and thus is a functionalderivative. In one embodiment, the nucleic acid comprises a sequencethat can bind canine pol I polypeptides and initiate (in vitro or invivo) transcription of an influenza vRNA in canine cells.

In certain embodiments, a nucleic acid sequence of the inventioncomprises, or alternatively consists of nucleotides −250 to −1 (inrelation to the first nucleotide transcribed from the promoter, alsoknown as the +1 nucleotide) of the sequence presented as SEQ ID NO: 1,or a functional derivative thereof. The +1 nucleotide for the 18Sribosomal RNA expressed from the canine pol I regulatory sequence foundin SEQ ID NO: 1 is the nucleotide at position 1804 of SEQ ID NO: 1.

In certain embodiments, the canine pol I regulatory sequence of theinvention comprises, or alternatively consists of an isolated nucleicacid (or the complement sequence thereof) that hybridizes understringent hybridization conditions to a nucleic acid comprising anucleic acid selected from the group consisting of: SEQ ID Nos 1-19 andcan initiate transcription of a gene operatively linked to theregulatory sequence in canine cells.

In one embodiment, the canine pol I regulatory sequence of the inventioncomprises a nucleic acid sequence that can bind a canine RNA pol Ipolypeptide and, in one embodiment, initiate transcription of a geneoperatively linked to the nucleotide sequence in canine cells. In oneembodiment, the nucleic acid comprises a sequence that can bind aeukaryotic pol I polypeptide and initiate (in vitro or in vivo)transcription of an influenza vRNA. In certain embodiments, binding ofcanine RNA pol I polypeptide to a canine pol I regulatory sequence isassayed with a nuclease protection assay. In certain embodiments,binding of canine RNA pol I polypeptide to a canine pol I regulatorysequence is assayed with a BIACORE system for assessing proteininteractions (Biacore International AG, Uppsala, Sweden).

In certain embodiments, the nucleic acid comprises a sequence that bindscanine RNA pol I. In certain embodiments, the sequence binds canine RNApol I with greater affinity than an RNA polymerase selected from thegroup consisting of: a primate RNA pol I, a human pol I, and a mouse polI. In certain embodiments, the sequence binds canine RNA pol I withgreater affinity than canine RNA pol II. In certain embodiments, thesequence binds canine RNA pol I with greater affinity than canine RNApol III. In certain embodiments, binding to a canine pol I regulatorysequence is assayed with a BIACORE system for assessing proteininteractions (Biacore International AG, Uppsala, Sweden).

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:2) TTGATGATTTTTCAAAGTCCTCCCGGAGATCACTGGCTTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGTCTCCACCGACCCGTATCGCCCCTCCTCCCCTCCCCCCCCCCCCCCGTTCCCTGGGTCGACCAGATAGCCCTGGGGGCTCCGTGGGGTGGGGGTGGGGGGGCGCCGTGGGGCAGGTTTTGGGGACAGTTGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTGCCCGAGATGAACATTTTTTGTTGCCAGGTAGGTGCTGACA.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:3) GGGCTCCGTGGGGTGGGGGTGGGGGGGCGCCGTGGGGCAGGTTTTGGGGACAGTTGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTGCCCGAGATGAACATTTTTTGTT GCCAGGTAGGTGCTGACA.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:4) GCCGTGGGGCAGGTTTTGGGGACAGTTGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTGCCCGAGATGAACATTTTTTGTTGCCAGGTAGGTGCTGACA.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:5) TGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTGCCCGAGATGAACATTTTTTGTTGCAG GTAGGTGCTGACA.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:6) GTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTGCCCGAGATGAACATTTTTTGTTGCCAGGTAGGTGCTGACA.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:7) AGGCGCGGTTATTTTCTTGCCCGAGATGAACATTTTTTGTTGCCAGGTAG GTGCTGACA.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:8) TTGATGATTTTTCAAAGTCCTCCCGGAGATCACTGGCTTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGTCTCCACCGACCCGTATCGCCCCTCCTCCCCTCCCCCCCCCCCCCCGTTCCCTGGGTCG ACCAGATAGCCCTG.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:9) TTGATGATTTTTCAAAGTCCTCCCGGAGATCACTGGCTTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGTCTCCACCGACCCGTATCGCCCCTCCTCCCCTCCCCCCCCCCCCCC.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:10) TTGATGATTTTTCAAAGTCCTCCCGGAGATCACTGGCTTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGTCTCCACCG ACCCGTATC.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:11) TTGATGATTTTTCAAAGTCCTCCCGGAGATCACTGGCTTGGCGGCG TGGCGGCGT.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:12) TTGATGATTTTTCAAAGTCCTCCCGGAGATCACTGGCTTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGTCTCCACCGACCCGTATCGCCCCTCCTCCCCTCCCCCCCCCCCCCCGTTCCCTGGGTCGACCAGATAGCCCTGGGGGCTCCGTGGGGTGGGGGTGGGGGGGCGCCGTGGGGCAGGTTTTGGGGACAGTTGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTGCCCGAG.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:13) GGCGGCGTGGCGGCGTGGCGGCGTGGCGGCGTGGCGTCTCCACCGACCCGTATCGCCCCTCCTCCCCTCCCCCCCCCCCCCCGTTCCCTGGGTCGACCAGATAGCCCTGGGGGCTCCGTGGGGTGGGGGTGGGGGGGCGCCGTGGGGCAGGTTTTGGGGACAGTTGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTGCCCGAG.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:14) GCCCCTCCTCCCCTCCCCCCCCCCCCCCGTTCCCTGGGTCGACCAGATAGCCCTGGGGGCTCCGTGGGGTGGGGGTGGGGGGGCGCCGTGGGGCAGGTTTTGGGGACAGTTGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTGCCCGAG.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:15) GGGCTCCGTGGGGTGGGGGTGGGGGGGCGCCGTGGGGCAGGTTTTGGGGACAGTTGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTGCCCGAG.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:16) GCCGTGGGGCAGGTTTTGGGGACAGTTGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTG CCCGAG.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:17) TGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCTTGCCCGAG.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:18) GGCGTGGCGTCTCCACCGACCCGTATCGCCCCTCCTCCCCTCCCCCCCCCCCCCCGTTCCCTGGGTCGACCAGATAGCCCTGGGGGCTCCGTGGGGTGGGGGTGGGGGGGCGCCGTGGGGCAGGTTTTGGGGACAGTTGGCCGTGTCACGGTCCCGGGAGGTCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGG TTATTTTCTTGCCCGAG.

In certain embodiments, the canine RNA pol I promoter comprises, oralternatively consists of, the following nucleotide sequence: (SEQ IDNO:19) TCGCGGTGACCTGTGGCTGGTCCCCGCCGGCAGGCGCGGTTATTTTCT TGCCCGAG.Vectors and Expression Vectors

In another aspect, the invention provides vectors that comprise anucleic acid of the invention, including expression vectors useful forrecombinantly rescuing a virus from cell culture. Generally, theexpression vectors are useful for rescuing any virus known to oneskilled in the art to require production of RNA with defined ends duringits life-cycle. For example, as discussed above, the influenza virusgenomic RNA should have a defined 5′ and 3′ end to be effectivelyreplicated and packaged in a recombinant system. See, also review inNeumann et al. (2002), 83:2635-2662, which is incorporated by referenceherein. The following discussion focuses on expression vectors suitablefor use with influenza; however, it should be noted that other virusescan also be rescued using the vectors of the present invention.

In accordance with the present invention, in one embodiment, cDNAencoding viral genomic RNA corresponding to each of the eight genomicsegments of influenza (segments may be from different influenza viruses,e.g., 6 from stain X and 2 from strain Y) can be inserted into arecombinant vector for manipulation and production of influenza viruses.A variety of vectors, including viral vectors, plasmids, cosmids, phage,and artificial chromosomes, can be employed in the context of theinvention. Typically, for ease of manipulation, the cDNA is insertedinto a plasmid vector, providing one or more origins of replicationfunctional in bacterial and eukaryotic cells, and, optionally, a markerconvenient for screening or selecting cells incorporating the plasmidsequence. See, e.g., Neumann et al., 1999, PNAS. USA 96:9345-9350.

In one embodiment, the vectors of the invention are bi-directionalexpression vectors capable of initiating transcription of a viralgenomic segment from the inserted cDNA in either direction, that is,giving rise to both (+) strand and (−) strand viral RNA molecules. Toeffect bi-directional transcription, each of the viral genomic segmentsis inserted into an expression vector having at least two independentpromoters, such that copies of viral genomic RNA are transcribed by afirst RNA polymerase promoter (e.g., a canine RNA pol I promoter), fromone strand, and viral mRNAs are synthesized from a second RNA polymerasepromoter (e.g., a canine RNA Pol II promoter or other promoter that caninitiate transcription by RNA pol II in canine cells). Accordingly, thetwo promoters can be arranged in opposite orientations flanking at leastone cloning site (i.e., a restriction enzyme recognition sequence)preferably a unique cloning site, suitable for insertion of viralgenomic RNA segments. Alternatively, an “ambisense” expression vectorcan be employed in which the (+) strand mRNA and the (−) strand viralRNA (as a cRNA) are transcribed from the same strand of the vector. Asdiscussed above, the pol I promoter for transcribing the viral genomicRNA is preferably a canine pol I promoter.

To ensure the correct 3′ end of each expressed vRNA or cRNA, each vRNAor cRNA expression vector can incorporate a ribozyme sequence orappropriate termination sequence (e.g., human, mouse, primate, or canineRNA polymerase I termination sequence) downstream of the RNA codingsequence. This may be, for example, the hepatitis delta virus genomicribozyme sequence or a functional derivative thereof, or the murine rDNAtermination sequence (Genbank Accession Number M12074). Alternatively,for example, a Pol I termination sequence may be employed (Neumann etal., 1994, Virology 202:477-479). The RNA expression vectors may beconstructed in the same manner as the vRNA expression vectors describedin Pleschka et al., 1996, J. Virol. 70:4188-4192; Hoffmann and Webster,2000, J. Gen Virol. 81:2843-2847; Hoffinann et al., 2002, Vaccine20:3165-3170; Fodor et al., 1999, J. Virol. 73:9679-9682; Neumann etal., 1999, P.N.A.S.USA 96:9345-9350; and Hoffinann et al., 2000,Virology 267:310-317, each of which is hereby incorporated by referencein its entirety.

In other systems, viral sequences transcribed by the pol I and pol IIpromoters can be transcribed from different expression vectors. In theseembodiments, vectors encoding each of the viral genomic segments underthe control of a canine regulatory sequence of the invention, e.g., acanine pol I promoter (“vRNA expression vectors”) and vectors encodingone or more viral polypeptides, e.g., influenza PA, PB1, PB2, and NPpolypeptides (“protein expression vectors”) under the control of a polII promoter can be used.

In either case, with regard to the pol II promoter, the influenza virusgenome segment to be expressed can be operably linked to an appropriatetranscription control sequence (promoter) to direct mRNA synthesis. Avariety of promoters are suitable for use in expression vectors forregulating transcription of influenza virus genome segments. In certainembodiments, the cytomegalovirus (CMV) DNA dependent RNA Polymerase II(Pol II) promoter is utilized. If desired, e.g., for regulatingconditional expression, other promoters can be substituted which induceRNA transcription under the specified conditions, or in the specifiedtissues or cells. Numerous viral and mammalian, e.g., human promotersare available, or can be isolated according to the specific applicationcontemplated. For example, alternative promoters obtained from thegenomes of animal and human viruses include such promoters as theadenovirus (such as Adenovirus 2), papilloma virus, hepatitis-B virus,and polyoma virus, and various retroviral promoters. Mammalian promotersinclude, among many others, the actin promoter, immunoglobulinpromoters, heat-shock promoters, and the like. In a specific embodiment,the regulatory sequence comprises the adenovirus 2 major late promoterlinked to the spliced tripartite leader sequence of human adenovirus 2,as described by Berg et al., Bio Techniques 14:972-978. In addition,bacteriophage promoters can be employed in conjunction with the cognateRNA polymerase, e.g., the T7 promoter.

Expression vectors used to express viral proteins, in particular viralproteins for RNP complex formation, will preferably express viralproteins homologous to the desired virus. The expression of viralproteins by these expression vectors may be regulated by any regulatorysequence known to those of skill in the art. The regulatory sequence maybe a constitutive promoter, an inducible promoter or a tissue-specificpromoter. Further examples of promoters which may be used to control theexpression of viral proteins in protein expression vectors include, butare not limited to, the SV40 early promoter region (Bernoist andChambon, 1981, Nature 290:304-310), the promoter contained in the 3′long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981,Proc. Natl. Acad. Sci. USA 78:1441-1445), the regulatory sequences ofthe metallothionein gene (Brinster et al., 1982, Nature 296:39-42);prokaryotic expression vectors such as the β-lactamase promoter(Villa-Kamaroff et al., 1978, Proc. Natl. Acad. Sci. USA 75:3727-3731),or the tac promoter (DeBoer et al., 1983, Proc. Natl. Acad. Sci. USA80:21-25); see also “Useful proteins from recombinant bacteria” inScientific American, 1980, 242:74-94; plant expression vectorscomprising the nopaline synthetase promoter region (Herrera-Estrella etal., Nature 303:209-213) or the cauliflower mosaic virus 35S RNApromoter (Gardner et al., 1981, Nucl. Acids Res. 9:2871), and thepromoter of the photosynthetic enzyme ribulose biphosphate carboxylase(Herrera-Estrella et al., 1984, Nature 310:115-120); promoter elementsfrom yeast or other fungi such as the Gal 4 promoter, the ADC (alcoholdehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkalinephosphatase promoter, and the following animal transcriptional controlregions, which exhibit tissue specificity and have been utilized intransgenic animals: elastase I gene control region which is active inpancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Omitz etal., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald,1987, Hepatology 7:425-515); insulin gene control region which is activein pancreatic beta cells (Hanahan, 1985, Nature 315:115-122),immunoglobulin gene control region which is active in lymphoid cells(Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444),mouse mammary tumor virus control region which is active in testicular,breast, lymphoid and mast cells (Leder et al, 1986, Cell 45:485-495),albumin gene control region which is active in liver (Pinkert et al.,1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control regionwhich is active in liver (Krumlauf et al, 1985, Mol. Cell. Biol.5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1-antitrypsingene control region which is active in the liver (Kelsey et al., 1987,Genes and Devel. 1: 161-171), beta-globin gene control region which isactive in myeloid cells (Mogram et al., 1985, Nature 315:338-340;Kollias et al., 1986, Cell 46:89-94; myelin basic protein gene controlregion which is active in oligodendrocyte cells in the brain (Readheadet al., 1987, Cell 48:703-712), myosin light chain-2 gene control regionwhich is active in skeletal muscle (Sani, 1985, Nature 314:283-286), andgonadotropic releasing hormone gene control region which is active inthe hypothalamus (Mason et al., 1986, Science 234:1372-1378).

In a specific embodiment, protein expression vectors of the inventioncomprise a promoter operably linked to a nucleic acid sequence, one ormore origins of replication, and, optionally, one or more selectablemarkers (e.g., an antibiotic resistance gene). In another embodiment, aprotein expression vector of the invention that is capable of producingbicistronic mRNA may be produced by inserting bicistronic mRNA sequence.Certain internal ribosome entry site (IRES) sequences may be utilized.Preferred IRES elements include, but are not limited to the mammalianBiP IRES and the hepatitis C virus IRES.

In one embodiment, a nucleic acid of the invention is inserted intoplasmid pAD3000 or a derivative thereof. See, U.S. patent applicationpublication 20050266026 and FIG. 10. Thus, in certain embodiments, theexpression vector is a bi-directional expression vector. In certainembodiments, the expression vector comprises a SV40 polyadenylationsignal flanking a segment of the influenza virus genome internal to thetwo promoters. In certain embodiments, the expression vector comprisesthe cytomegalovirus (CMV) DNA dependent RNA Pol II promoter.

Vectors containing gene inserts can be identified by, e.g., threegeneral approaches:(a) nucleic acid hybridization; (b) presence orabsence of “marker” gene functions and, in the case of expressionvectors, (c) expression of inserted sequences. In the first approach,the presence of the viral gene inserted in an vector(s) can be detectedby nucleic acid hybridization using probes comprising sequences that arehomologous to the inserted gene(s). In the second approach, therecombinant vector/host system can be identified and selected based uponthe presence or absence of certain “marker” gene functions (e.g.,resistance to antibiotics or transformation phenotype) caused by theinsertion of the gene(s) in the vector(s). In the third approach,expression vectors can be identified by assaying the gene productexpressed. Such assays can be based, for example, on the physical orfunctional properties of the viral protein in in vitro assay systems,e.g., binding of viral proteins to antibodies.

In a specific embodiment, one or more protein expression vectors encodeand express the viral proteins necessary for the formation of RNPcomplexes. In another embodiment, one or more protein expression vectorsencode and express the viral proteins necessary to form viral particles.In yet another embodiment, one or more protein expression vectors encodeand express the all of the viral proteins of a particularnegative-strand RNA virus.

Transcription from expression vectors can optionally be increased byincluding an enhancer sequence. Enhancers are typically short, e.g.,10-500 bp, cis-acting DNA elements that act in concert with a promoterto increase transcription. Many enhancer sequences have been isolatedfrom mammalian genes (hemoglobin, elastase, albumin, alpha.-fetoprotein,and insulin), and eukaryotic cell viruses. The enhancer can be splicedinto the vector at a position 5′ or 3′ to the heterologous codingsequence, but is typically inserted at a site 5′ to the promoter.Typically, the promoter, and if desired, additional transcriptionenhancing sequences are chosen to optimize expression in the host celltype into which the heterologous DNA is to be introduced (Scharf et al.(1994) Heat stress promoters and transcription factors Results ProblCell Differ 20:125-62; Kriegler et al. (1990) Assembly of enhancers,promoters, and splice signals to control expression of transferred genesMethods in Enzymol 185: 512-27). Optionally, the amplicon can alsocontain a ribosome binding site or an internal ribosome entry site(IRES) for translation initiation.

The expression vectors of the invention can also include sequences forthe termination of transcription and for stabilizing the mRNA, such as apolyadenylation site or a termination sequence (e.g., human, mouse,primate, or canine RNA polymerase I termination sequence). Suchsequences are commonly available from the 5′ and, occasionally 3′,untranslated regions of eukaryotic or viral DNAs or cDNAs. In someembodiments, the SV40 polyadenylation sequences provide apolyadenylation signal.

In addition, as described above, the vectors optionally include one ormore selectable marker genes to provide a phenotypic trait for selectionof transformed host cells, in addition to genes previously listed,markers such as dihydrofolate reductase or neomycin resistance aresuitable for selection in eukaryotic cell culture.

The expression vector containing the appropriate DNA sequence asdescribed above, as well as an appropriate promoter or control sequence,can be employed to transform a host cell permitting expression of theprotein. While the expression vectors of the invention can be replicatedin bacterial cells, most frequently it will be desirable to introducethem into mammalian cells, e.g., Vero cells, BHK cells, MDCK cell, 293cells, COS cells, more preferably MDCK cells, for the purpose ofexpression.

The expression vectors of the invention can be used to directing theexpressing of genomic vRNA(s) or corresponding cRNA(s) which have one ormore mutations (e.g., removal or inactivation of a polybasic cleavagesite in the HA gene of particular influenza pandemic strains such as H5N1). These mutations may result in the attenuation of the virus. Forexample, the vRNA segments may be the vRNA segments of an influenza Avirus having an attenuated base pair substitution in a pan-handle duplexpromoter region, in particular, for example, the known attenuating basepair substitution of A for C and U for G at position 11-12′ in theduplex region of the NA-specific vRNA (Fodor et al., 1998, J. Virol.6923-6290). By using the methods of the invention to produce recombinantnegative-strand RNA virus, new attenuating mutations may be identified.

Further, any of the expression vectors described in U.S. Pat. Nos.6,951,754, 6,887,699, 6,649,372, 6,544,785, 6,001,634, 5,854,037,5,824,536, 5,840,520, 5,820,871, 5,786,199, and 5,166,057 and U.S.Patent Application Publication Nos. 20060019350, 20050158342,20050037487, 20050266026, 20050186563, 20050221489, 20050032043,20040142003, 20030035814, and 20020164770 can be used in accordance withthe present invention. Generally, the vectors described in thesepublications can be adapted for use in accordance with the presentinvention by introducing a nucleic acid of the invention (e.g., a canineregulatory sequence of the invention such as a canine poll promotersequence) as described herein into the expression vectors to directsynthesis of viral vRNA or cRNA.

6.3.1 Additional Expression Elements

Most commonly, the genome segment encoding the influenza virus proteinincludes any additional sequences necessary for its expression,including translation into a functional viral protein. In othersituations, a minigene, or other artificial construct encoding the viralproteins, e.g., an HA or NA protein, can be employed. In this case, itis often desirable to include specific initiation signals which aid inthe efficient translation of the heterologous coding sequence. Thesesignals can include, e.g., the ATG initiation codon and adjacentsequences. To insure translation of the entire insert, the initiationcodon is inserted in the correct reading frame relative to the viralprotein. Exogenous transcriptional elements and initiation codons can beof various origins, both natural and synthetic. The efficiency ofexpression can be enhanced by the inclusion of enhancers appropriate tothe cell system in use.

If desired, polynucleotide sequences encoding additional expressedelements, such as signal sequences, secretion or localization sequences,and the like can be incorporated into the vector, usually, in-frame withthe polynucleotide sequence of interest, e.g., to target polypeptideexpression to a desired cellular compartment, membrane, or organelle, orinto the cell culture media. Such sequences are known to those of skill,and include secretion leader peptides, organelle targeting sequences(e.g., nuclear localization sequences, ER retention signals,mitochondrial transit sequences), membrane localization/anchor sequences(e.g., stop transfer sequences, GPI anchor sequences), and the like.

6.4 Expression Vectors for Making Chimeric Viruses

The expression vectors of the invention can also be used to makechimeric viruses that express sequences heterologous to a viral genome.Expression vectors directing the expression of vRNA(s) or correspondingcRNA(s) are introduced into host cells along with expression vectorsdirect the expression of viral proteins to generate novel infectiousrecombinant negative-strand RNA viruses or chimeric viruses. See, e.g.,U.S. patent application publication no. US20040002061. Heterologoussequences which may be engineered into these viruses include antisensenucleic acids and nucleic acid such as a ribozyme. Alternatively,heterologous sequences which express a peptide or polypeptide may beengineered into these viruses. Heterologous sequences encoding thefollowing peptides or polypeptides may be engineered into these virusesinclude: 1) antigens that are characteristic of a pathogen; 2) antigensthat are characteristic of autoimmune disease; 3) antigens that arecharacteristic of an allergen; and 4) antigens that are characteristicof a tumor. For example, heterologous gene sequences that can beengineered into the chimeric viruses of the invention include, but arenot limited to, epitopes of human immunodeficiency virus (HIV) such asgp160; hepatitis B virus surface antigen (HBsAg); the glycoproteins ofherpes virus (e.g., gD, gE); VP1 of poliovirus; and antigenicdeterminants of nonviral pathogens such as bacteria and parasites toname but a few.

Antigens that are characteristic of autoimmune disease typically will bederived from the cell surface, cytoplasm, nucleus, mitochondria and thelike of mammalian tissues, including antigens characteristic of diabetesmellitus, multiple sclerosis, systemic lupus erythematosus, rheumatoidarthritis, pernicious anemia, Addison's disease, scleroderma, autoimmuneatrophic gastritis, juvenile diabetes, and discoid lupus erythromatosus.

Antigens that are allergens are generally proteins or glycoproteins,including antigenis derived from pollens, dust, molds, spores, dander,insects and foods.

Antigens that are characteristic of tumor antigens typically will bederived from the cell surface, cytoplasm, nucleus, organelles and thelike of cells of tumor tissue. Examples include antigens characteristicof tumor proteins, including proteins encoded by mutated oncogenes;viral proteins associated with tumors; and glycoproteins. Tumorsinclude, but are not limited to, those derived from the types of cancer:lip, nasopharynx, pharynx and oral cavity, esophagus, stomach, colon,rectum, liver, gall bladder, pancreas, larynx, lung and bronchus,melanoma of skin, breast, cervix, uterine, ovary, bladder, kidney,uterus, brain and other parts of the nervous system, thyroid, prostate,testes, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma andleukemia.

In one specific embodiment of the invention, the heterologous sequencesare derived from the genome of human immunodeficiency virus (HIV),preferably human immunodeficiency virus-1 or human immunodeficiencyvirus-2. In another embodiment of the invention, the heterologous codingsequences may be inserted within an negative-strand RNA virus genecoding sequence such that a chimeric gene product is expressed whichcontains the heterologous peptide sequence within the viral protein. Insuch an embodiment of the invention, the heterologous sequences may alsobe derived from the genome of a human immunodeficiency virus, preferablyof human immunodeficiency virus-1 or human immunodeficiency virus-2.

In instances whereby the heterologous sequences are HIV-derived, suchsequences may include, but are not limited to sequences derived from theenv gene (i.e., sequences encoding all or part of gp160, gp120, and/orgp41), the pol gene (i.e., sequences encoding all or part of reversetranscriptase, endonuclease, protease, and/or integrase), the gag gene(i.e., sequences encoding all or part of p7, p6, p55, p17/18, p24/25)tat, rev, nef, vif, vpu, vpr, and/or vpx.

One approach for constructing these hybrid molecules is to insert theheterologous coding sequence into a DNA complement of a negative-strandRNA virus gene so that the heterologous sequence is flanked by the viralsequences required for viral polymerase activity; e.g., a canine RNA polI promoter and a polyadenylation site. In an alternative approach,oligonucleotides encoding a canine RNA pol I promoter, e.g., thecomplement of the 3′-terminus or both termini of the virus genomicsegments can be ligated to the heterologous coding sequence to constructthe hybrid molecule. The placement of a foreign gene or segment of aforeign gene within a target sequence was formerly dictated by thepresence of appropriate restriction enzyme sites within the targetsequence. However, recent advances in molecular biology have lessenedthis problem greatly. Restriction enzyme sites can readily be placedanywhere within a target sequence through the use of site-directedmutagenesis (e.g., see, for example, the techniques described by Kunkel,1985, Proc. Natl. Acad. Sci. U.S.A. 82:488). Variations in polymerasechain reaction (PCR) technology, described, also allow for the specificinsertion of sequences (i.e., restriction enzyme sites) and allow forthe facile construction of hybrid molecules. Alternatively, PCRreactions could be used to prepare recombinant templates without theneed of cloning. For example, PCR reactions could be used to preparedouble-stranded DNA molecules containing a DNA-directed RNA polymerasepromoter (e.g., bacteriophase T3, T7 or SP6) and the hybrid sequencecontaining the heterologous gene and a canine RNA pol I promoter. RNAtemplates could then be transcribed directly from this recombinant DNA.In yet another embodiment, the recombinant vRNAs or corresponding cRNAsmay be prepared by ligating RNAs specifying the negative polarity of theheterologous gene and the canine RNA pol I promoter using an RNA ligase.

Bicistronic mRNA could be constructed to permit internal initiation oftranslation of viral sequences and allow for the expression of foreignprotein coding sequences from the regular terminal initiation site.Alternatively, a bicistronic mRNA sequence may be constructed whereinthe viral sequence is translated from the regular terminal open readingframe, while the foreign sequence is initiated from an internal site.Certain internal ribosome entry site (IRES) sequences may be utilized.The IRES sequences which are chosen should be short enough to notinterfere with virus packaging limitations. Thus, it is preferable thatthe IRES chosen for such a bicistronic approach be no more than 500nucleotides in length, with less than 250 nucleotides being preferred.Further, it is preferable that the IRES utilized not share sequence orstructural homology with picornaviral elements. Preferred IRES elementsinclude, but are not limited to the mammalian BiP FRES and the hepatitisC virus IRES.

Alternatively, a foreign protein may be expressed from an internaltranscriptional unit in which the transcriptional unit has an initiationsite and polyadenylation site. In another embodiment, the foreign geneis inserted into a negative-strand RNA virus gene such that theresulting expressed protein is a fusion protein.

6.5 Methods of Generating Recombinant Viruses

The present invention provides methods of generating infectiousrecombinant negative-strand RNA virus by introducing protein expressionvectors and vRNA or corresponding cRNA expressing expression vectors ofthe invention into host cells in the absence of helper virus.Preferably, the host cells are canine cells, e.g., MDCK cells. Thepresent invention also provides methods of generating infectiousrecombinant negative-strand RNA virus by introducing protein expressionvectors and vRNA or corresponding cRNA expressing expression vectors ofthe invention into host cells in the presence of helper virus.Preferably, the host cells are canine cells, e.g., MDCK cells.

Protein expression vectors and expression vectors directing theexpression of vRNAs or corresponding cRNAs can be introduced into hostcells using any technique known to those of skill in the art withoutlimitation. For example, expression vectors of the invention can beintroduced into host cells by employing electroporation, DEAE-dextran,calcium phosphate precipitation, liposomes, microinjection, andmicroparticle-bombardment (see, e.g., Sambrook et al., MolecularCloning: A Laboratory Manual, 2 ed., 1989, Cold Spring Harbor Press,Cold Spring Harbor, N.Y.). The expression vectors of the invention maybe introduced into host cells simultaneously or sequentially.

In one embodiment, one or more expression vectors directing theexpression of vRNA(s) or corresponding cRNA(s) are introduced into hostcells prior to the introduction of expression vectors directing theexpression of viral proteins. In another embodiment, one or moreexpression vectors directing the expression of viral proteins areintroduced into host cells prior to the introduction of the one or moreexpression vectors directing the expression of vRNA(s) or correspondingcRNA(s). In accordance with these embodiments, the expression vectorsdirecting the expression of the vRNA(s) or corresponding cRNA(s) mayintroduced together or separately in different transfections. Further,in accordance with these embodiments, the expression vectors directingthe expression of the viral proteins can be introduced together orseparately in different transfections.

In another embodiment, one or more expression vectors directing theexpression of vRNA(s) or corresponding cRNA(s) and one or moreexpression vectors directing the expression of viral proteins areintroduced into host cells simultaneously. In certain embodiments, allof the expression vectors are introduced into host cells usingliposomes.

Appropriate amounts and ratios of the expression vectors for carryingout a method of the invention may be determined by routineexperimentation. As guidance, in the case of liposomal transfection orcalcium precipitation of plasmids into the host cells, it is envisagedthat each plasmid may be employed at a few μgs, e.g., 1 to 10 μg, forexample, diluted to a final total DNA concentration of about 0.1 μg/mlprior to mixing with transfection reagent in conventional manner. It maybe preferred to use vectors expressing NP and/or RNA-dependent RNApolymerase subunits at a higher concentration than those expressing vRNAsegments. One skilled in the art will appreciate that the amounts andratios of the expression vectors may vary depending upon the host cells.

In one embodiment, at least 0.5 μg, preferably at least 1 μg, at least2.5 μg, at least 5 μg, at least 8 μg, at least 10 μg, at least 15 μg, atleast 20 μg, at least 25 μg, or at least 50 μg of one or more proteinexpression vectors of the invention are introduced into host cells togenerate infectious recombinant negative-strand RNA virus. In anotherembodiment, at least 0.5 μg, preferably at least 1 μg, at least 2.5 μg,at least 5 μg, at least 8 μg, at least 10 μg, at least 15 μg, at least20 μg, at least 25 μg or at least 50 μg of one or more expressionvectors of the invention directing the expression of vRNAs or cRNAs areintroduced into host cells to generate infectious recombinantnegative-strand RNA virus.

Host cells which may be used to generate the negative-strand RNA virusesof the invention include primary cells, cultured or secondary cells, andtransformed or immortalized cells (e.g., 293 cells, 293T cells, CHOcells, Vero cells, PK, MDBK, OMK and MDCK cells). Host cells arepreferably animal cells, more preferably mammalian cells, and mostpreferably canine cells. In a preferred embodiment, infectiousrecombinant negative-strand RNA viruses of the invention are generatedin MDCK cells.

The present invention provides methods of generating infectiousrecombinant negative-strand RNA virus in stably transduced host celllines. The stably transduced host cell lines of the invention may beproduced by introducing cDNA controlled by appropriate expressioncontrol elements (e.g., promoter, enhancer, sequences, transcriptiontermination sequences, polyadenylation sites, etc.), and a selectablemarker into host cells. Following the introduction of the foreign DNA,the transduced cells may be allowed to grow for 1-2 days in an enrichedmedia, and then are switched to a selective media. The selectable markerconfers resistance to the cells and allows the cells to stably integratethe DNA into their chromosomes. Transduced host cells with the DNAstably integrated can be cloned and expanded into cell lines.

A number of selection systems may be used, including but not limited tothe herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska &Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adeninephosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes can beemployed in tk-, hgprt- or aprt-cells, respectively. Also,antimetabolite resistance can be used as the basis of selection fordhfr, which confers resistance to methotrexate (Wigler et al., 1980,Natl. Acad. Sci. USA 77:3567; O'Hare et al., 1981, Proc. Natl. Acad.Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid(Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, whichconfers resistance to the aminoglycoside G-418 (Colberre-Garapin et al.,1981, J. Mol. Biol. 150:1); and hygro, which confers resistance tohygromycin (Santerre et al., 1984, Gene 30:147) genes.

The infectious recombinant negative-strand RNA viruses generated bymethods of the invention which are not attenuated, may be attenuated orkilled by, for example, classic methods. For example, recombinantnegative-strand RNA viruses of the invention may be killed by heat orformalin treatment, so that the virus is not capable of replicating.Recombinant negative-strand RNA viruses of the invention which are notattenuated may be attenuated by, e.g., passage through unnatural hoststo produce progeny viruses which are immunogenic, but not pathogenic.

Attenuated, live or killed viruses produced in accordance with theinvention may subsequently be incorporated into a vaccine composition inconventional manner or used to produce additional virus, e.g., in eggs.Where such a virus has a chimeric vRNA segment as discussed above whichencodes a foreign antigen, it may be formulated to achieve vaccinationagainst more than one pathogen simultaneously. Attenuated recombinantviruses produced in accordance with the invention which possess achimeric vRNA segment may also be designed for other therapeutic uses,e.g., an anti-tumor agent or gene therapy tool, in which case productionof the virus will be followed by its incorporation into an appropriatepharmaceutical composition together with a pharmaceutically acceptablecarrier or diluent.

Helper virus free rescue in accordance with the invention isparticularly favored for generation of reassortant viruses, especiallyreassortant influenza viruses desired for vaccine use particularly sinceselection methods are not needed to rid the culture of helper virus.

The methods of the present invention may be modified to incorporateaspects of methods known to those skilled in the art, in order toimprove efficiency of rescue of infectious viral particles. For example,the reverse genetics technique involves the preparation of syntheticrecombinant viral RNAs that contain the non-coding regions of thenegative strand virus RNA which are essential for the recognition byviral polymerases and for packaging signals necessary to generate amature virion. The recombinant RNAs are synthesized from a recombinantDNA template and reconstituted in vitro with purified viral polymerasecomplex to form recombinant ribonucleoprotein (RNPs) which can be usedto transfect cells. A more efficient transfection is achieved if theviral polymerase proteins are present during transcription of thesynthetic RNAs either in vitro or in vivo. The synthetic recombinantRNPs can be rescued into infectious virus particles. The foregoingtechniques are described in U.S. Pat. No. 5,166,057 issued Nov. 24,1992; in U.S. Pat. No. 5,854,037 issued Dec. 29, 1998; in U.S. Pat. No.5,789,229 issued Aug. 4, 1998; in European Patent Publication EP0702085A1, published Feb. 20, 1996; in U.S. patent application Ser. No.09/152,845; in International Patent Publications PCR WO97/12032published Apr. 3, 1997; WO96/34625 published Nov. 7, 1996; in EuropeanPatent Publication EP-A780475; WO99/02657 published Jan. 21, 1999;WO98/53078 published Nov. 26, 1998; WO98/02530 published Jan. 22, 1998;WO99/15672 published Apr. 1, 1999; WO98/13501 published Apr. 2, 1998;WO97/06720 published Feb. 20, 1997; and EPO 780 47SA1 published Jun. 25,1997, each of which is incorporated by reference herein in its entirety.

6.5.1 Specific Segmented Negative-Strand RNA Virus Embodiments

The present invention provides a method for generating in cultured cellsinfectious recombinant viral particles of a segmented negative-strandRNA virus having greater than 3 genomic vRNA segments, for example aninfluenza virus such as an influenza A virus, said method comprising:(a) introducing into. a population of cells capable of supporting growthof said virus a first set of expression vectors capable of expressing insaid cells genomic vRNA segments to provide the complete genomic vRNAsegments of said virus; (b) introducing into said cells a second set ofexpression vectors capable of expressing mRNA encoding one or morepolypeptides of said virus; and (c) culturing said cells whereby saidviral particles are produced. In certain embodiments, the cells arecanine cells. In certain embodiments, the cells are MDCK cells. Incertain embodiments, the recombinant virus is influenza A or B virus. Incertain embodiments, the first set of expression vectors is contained in1-8 plasmids. In certain embodiments, the first set of expressionvectors is contained in one plasmid. In certain embodiments, the secondset of expression vectors is contained in 1-8 plasmids. In certainembodiments, the second set of expression vectors is contained in oneplasmid. In certain embodiments, the first, second, or both sets ofexpression vectors are introduced by electroporation. In certainembodiments, the first set of expression vectors encode each vRNAsegment of an influenza virus. In certain embodiments, the second set ofexpression vectors encode the mRNA of one or more or all influenzapolypeptides. In certain embodiments, the first set or second set ofexpression vectors (or both sets) comprise a nucleic acid of theinvention, for example, a canine RNA pol I regulatory sequence of theinvention (e.g., a canine RNA pol I promoter). In certain embodiments,the first set or second set of expression vectors (or both sets) encodea vRNA or mRNA of a second virus. For instance, a set of vectorscomprises one or more vectors encoding the HA and/or NA mRNA and/or vRNAof a second influenza virus. In one embodiment, helper virus is used inthe method. In one embodiment, the cultured cells used in the method arecanine cells.

The present invention provides a method for generating in cultured cellsinfectious recombinant viral particles of a segmented negative-strandRNA virus having greater than 3 genomic vRNA segments, for example aninfluenza virus such as an influenza A virus, said method comprising:(a) introducing into a population of cells capable of supporting growthof said virus a set of expression vectors capable of both expressing insaid cells genomic vRNA segments to provide the complete genomic vRNAsegments of said virus and capable of expressing mRNA encoding one ormore polypeptides of said virus; (b) culturing said cells whereby saidviral particles are produced. In certain embodiments, the cells arecanine cells. In certain embodiments, the cells are MDCK cells. Incertain embodiments, the virus is influenza A or B virus. In certainembodiments, the set of expression vectors are comprised in 1-17plasmids. In certain embodiments, the set of expression vectors iscontained in 1-8 plasmid. In certain embodiments, the set of expressionvectors is contained in 1-3 plasmids. In certain embodiments, the set ofexpression vectors is contained in one plasmid. In certain embodiments,the sets of expression vectors are introduced by electroporation. Incertain embodiments, the set of expression vectors encode each vRNAsegment of an influenza virus. In certain embodiments, the set ofexpression vectors encode the mRNA of one or more influenza polypeptide.In certain embodiments, the set of expression vectors encode each vRNAsegment of an influenza virus and the mRNA of one or more influenzapolypeptide. In certain embodiments, the set of expression vectorscomprise a nucleic acid of the invention, for example, a canine RNA polI regulatory sequence of the invention (e.g., a canine RNA pol Ipromoter). In certain embodiments, the set of expression vectors encodea vRNA or mRNA of a second virus. For instance, the set of vectorscomprises one or more vectors encoding the HA and/or NA mRNA and/or vRNAof a second influenza virus. In certain embodiments, the first set orsecond set of expression vectors (or both sets) encode a vRNA or mRNA ofa second virus. For instance, a set of vectors comprises one or morevectors encoding the HA and/or NA mRNA and/or vRNA of a second influenzavirus. In one embodiment, helper virus is used in the method. In oneembodiment, the cultured cells used in the method are canine cells.

The present invention provides a method for generating in cultured cellsinfectious recombinant viral particles of a negative-strand RNA virus,said method comprising: (a) introducing into a population of cellscapable of supporting growth of said virus a first set of expressionvectors capable of expressing in said cells genomic vRNA to provide thecomplete genomic vRNA of said virus; (b) introducing into said cells asecond set of expression vectors capable of expressing mRNA encoding oneor more polypeptides of said virus; and (c) culturing said cells wherebysaid viral particles are produced. In certain embodiments, the cells arecanine cells. In certain embodiments, the cells are MDCK cells. Incertain embodiments, the virus is influenza B virus. In certainembodiments, the first set of expression vectors is contained in 1-8plasmids. In certain embodiments, the first set of expression vectors iscontained in one plasmid. In certain embodiments, the second set ofexpression vectors is contained in 1-8 plasmids. In certain embodiments,the second set of expression vectors is contained in one plasmid. Incertain embodiments, the first, second, or both sets of expressionvectors are introduced by electroporation. In certain embodiments, thefirst set of expression vectors encode each vRNA segment of an influenzavirus. In certain embodiments, the second set of expression vectorsencode the mRNA of one or more influenza polypeptide. In certainembodiments, the first set or second set of expression vectors (or bothsets) comprise a nucleic acid of the invention, for example, a canineRNA pol I regulatory sequence of the invention (e.g., a canine RNA pol Ipromoter). In one embodiment, helper virus is used in the method. In oneembodiment, the cultured cells used in the method are canine cells.

The present invention provides a method for generating in cultured cellsinfectious viral particles of a negative-strand RNA virus, said methodcomprising: (a) introducing into a population of cells capable ofsupporting growth of said virus a set of expression vectors capable ofboth expressing in said cells genomic vRNA to provide the completegenomic vRNA of said virus and capable of expressing mRNA encoding oneor more polypeptides of said virus; (b) culturing said cells wherebysaid viral particles are produced. In certain embodiments, the cells arecanine cells. In certain embodiments, the cells are MDCK cells. Incertain embodiments, the virus is influenza B virus. In certainembodiments, the set of expression vectors is contained in 1-17plasmids. In certain embodiments, the set of expression vectors iscontained in 1-8 plasmid. In certain embodiments, the set of expressionvectors is contained in 1-3 plasmids. In certain embodiments, the setsof expression vectors are introduced by electroporation. In certainembodiments, the set of expression vectors encode each vRNA segment ofan influenza virus. In certain embodiments, the set of expressionvectors encode the mRNA of one or more influenza polypeptide. In certainembodiments, the set of expression vectors encode each vRNA segment ofan influenza virus and the mRNA of one or more influenza polypeptide. Incertain embodiments, the set of expression vectors comprise a nucleicacid of the invention, for example, a canine RNA pol I regulatorysequence of the invention (e.g., a canine RNA pol I promoter). Incertain embodiments, the set of expression vectors encode a vRNA or mRNAof a second virus. For instance, the set of vectors comprises one ormore vectors encoding the HA and/or NA mRNA and/or vRNA of a secondinfluenza virus. In one embodiment, helper virus is used in the method.In one embodiment, the cultured cells used in the method are caninecells.

The present invention provides a method for generating in culturedcanine cells infectious viral particles of a segmented negative-strandRNA virus having greater than 3 genomic vRNA segments, for example aninfluenza virus such as an influenza A virus, said method comprising:(a) providing a first population of canine cells capable of supportinggrowth of said virus and having introduced a first set of expressionvectors capable of directly expressing in said canine cells genomic vRNAsegments to provide the complete genomic vRNA segments of said virus, orthe corresponding cRNAs, in the absence of a helper virus to provide anysuch RNA segment, said canine cells also being capable of providing anucleoprotein and RNA-dependent RNA polymerase whereby RNP complexescontaining the genomic vRNA segments of said virus can be formed andsaid viral particles can be assembled within said canine cells; and (b)culturing said canine cells whereby said viral particles are produced.In certain embodiments, the canine cells are MDCK cells.

The present invention also provides a method for generating in culturedcanine cells infectious viral particles of a segmented negative-strandRNA virus, said method comprising:(i) providing a first population ofcanine cells which are capable of supporting the growth of said virusand which are modified so as to be capable of providing (a) the genomicvRNAs of said virus in the absence of a helper virus and (b) anucleoprotein and RNA-dependent RNA polymerase whereby RNA complexescontaining said genomic vRNAs can be formed and said viral particles canbe assembled, said genomic vRNAs being directly expressed in said cellsunder the control of a canine RNA Pol I regulatory sequence, orfunctional derivative thereof; and (ii) culturing said canine cellswhereby said viral particles are produced.

The present specification also provides a method for generating incultured cells infectious viral particles of a segmented negative-strandRNA virus, said method comprising: (i) providing a population of caninecells which are capable of supporting the growth of said virus and whichare modified so as be capable of providing (a) the genomic vRNAs of saidvirus in the absence of a helper virus and (b) a nucleoprotein andRNA-dependent RNA polymerase whereby RNP complex or complexes containingsaid genomic vRNAs can be formed and said viral particles can beassembled, said genomic RNAs being directly expressed in said caninecells under the control of a canine RNA Pol I regulatory sequence or afunctional derivative thereof, e.g., a canine RNA Pol I promoter asdescribed above; and (ii) culturing said canine cells whereby said viralparticles are produced.

In a specific embodiment, an infectious recombinant negative-strand RNAvirus having, at least 4, at least 5, at least 6, at least 7, or atleast 8 genomic vRNA segments in a canine host cell is generated usingthe methods described herein.

In a specific embodiment, the present invention provides for methods ofgenerating infectious recombinant influenza virus in host cells usingexpression vectors to express the vRNA segments or corresponding cRNAsand influenza virus proteins, in particular PB1, PB2, PA and NA. Inaccordance with this embodiment, helper virus may or may not be includedto generate the infectious recombinant influenza viruses.

The infectious recombinant influenza viruses of the invention may or maynot replicate and produce progeny. Preferably, the infectiousrecombinant influenza viruses of the invention are attenuated.Attenuated infectious recombinant influenza viruses may, for example,have a mutation in the NS1 gene.

In certain embodiments, an infectious recombinant viruses of theinvention can be used to produce other viruses useful to prepare avaccine composition of the invention. In one embodiment, recombinant orreassortant viruses produced by a method of the invention are used forthe production of additional virus for use as a vaccine. For example, apopulation of recombinant or reassortant viruses produced by the methodsof the invention which incorporate a canine RNA pol I regulatorysequence of the invention (e.g., a canine RNA pol I promoter).Subsequently, the population of viruses is grown in eggs or anotherculture such that additional viruses are produced for the preparation ofvaccines or an immunogenic composition.

In certain embodiments, the infectious recombinant influenza viruses ofthe invention express heterologous (i.e., non-influenza virus)sequences. In another embodiment, the infectious recombinant influenzaviruses of the invention express influenza virus proteins from differentinfluenza strains. In yet another preferred embodiment, the infectiousrecombinant influenza viruses of the invention express fusion proteins.

6.5.2 Introduction of Vectors into Host Cells

Vectors comprising influenza genome segments can be introduced (e.g.,transfected) into host cells according to methods well known in the art(see, e.g., U.S. patent application publication nos. US20050266026 and20050158342) for introducing heterologous nucleic acids into eukaryoticcells, including, e.g., calcium phosphate co-precipitation,electroporation, microinjection, lipofection, and transfection employingpolyamine transfection reagents. For example, vectors, e.g., plasmids,can be transfected into host cells, such as, e.g., MDCK cells, COScells, 293T cells, or combinations thereof, using the polyaminetransfection reagent TransIT-LT1 (Mirus) according to the manufacturer'sinstructions. Approximately 1 μg of each vector to be introduced intothe population of host cells can be combined with approximately 2 μl ofTransIT-LT 1 diluted in 160 μl medium, preferably serum-free medium, ina total volume of 200 μl. The DNA:transfection reagent mixtures can beincubated at room temperature for 45 min followed by addition of 800 μlof medium. The transfection mixture is then added to the host cells, andthe cells are cultured as described above. Accordingly, for theproduction of recombinant or reassortant viruses in cell culture,vectors incorporating each of the 8 genome segments, (PB2, PB1, PA, NP,M, NS, HA and NA) are mixed with approximately 20 μl TransIT-LT1 andtransfected into host cells. Optionally, serum-containing medium isreplaced prior to transfection with serum-free medium, e.g., Opti-MEM I,and incubated for 4-6 hours.

Alternatively, electroporation can be employed to introduce vectorsincorporating influenza genome segments into host cells. See, e.g., U.S.patent application publications US20050266026 and 20050158342, which areincorporated by reference herein. For example, plasmid vectorsincorporating an influenza A or influenza B virus are introduced intoMDCK cells using electroporation according to the following procedure.In brief, 5×10⁶ MDCK cells, e.g., grown in Modified Eagle's Medium (MEM)supplemented with 10% Fetal Bovine Serum (FBS) are resuspended in 0.4 mlOptiMEM and placed in an electroporation cuvette. Twenty micrograms ofDNA in a volume of up to 25 μl is added to the cells in the cuvette,which is then mixed gently by tapping. Electroporation is performedaccording to the manufacturer's instructions (e.g., BioRad Gene PulserII with Capacitance Extender Plus connected) at 300 volts, 950microFarads with a time constant of between 28-33 msec. The cells areremixed by gently tapping and approximately 1-2 minutes followingelectroporation 0.7 ml MEM with 10% FBS is added directly to thecuvette. The cells are then transferred to two wells of a standard 6well tissue culture dish containing 2 ml MEM, 10% FBS or OPTI-MEMwithout serum. The cuvette is washed to recover any remaining cells andthe wash suspension is divided between the two wells. Final volume isapproximately 3.5 mls. The cells are then incubated under conditionspermissive for viral growth, e.g., at approximately 33° C. for coldadapted strains.

Further guidance on introduction of vectors into host cells may befound, for example, in U.S. Pat. Nos. 6,951,754, 6,887,699, 6,649,372,6,544,785, 6,001,634, 5,854,037, 5,824,536, 5,840,520, 5,820,871,5,786,199, and 5,166,057 and U.S. Patent Application Publication Nos.20060019350, 20050158342, 20050037487, 20050266026, 20050186563,20050221489, 20050032043, 20040142003, 20030035814, and 20020164770.

6.6 Cell Culture

Typically, propagation of the virus is accomplished in the mediacompositions in which the host cell is commonly cultured. Suitable hostcells for the replication of influenza virus include, e.g., Vero cells,Per.C6 cells, BHK cells, MDCK cells, 293 cells and COS cells, including293T cells, COS7 cells. MDCK cells are preferred in the context of thepresent invention. Use of non-tumorigenic MDCK cells as host cells isalso an embodiment of the invention. Co-cultures including two of theabove cell lines, e.g., MDCK cells and either 293T or COS cells can alsobe employed at a ratio, e.g., of 1:1, to improve replication efficiency.See, e.g., 20050158342. Typically, cells are cultured in a standardcommercial culture medium, such as Dulbecco's modified Eagle's mediumsupplemented with serum (e.g., 10% fetal bovine serum), or in serum freemedium, under controlled humidity and CO₂ concentration suitable formaintaining neutral buffered pH (e.g., at pH between 7.0 and 7.2).Optionally, the medium contains antibiotics to prevent bacterial growth,e.g., penicillin, streptomycin, etc., and/or additional nutrients, suchas L-glutamine, sodium pyruvate, non-essential amino acids, additionalsupplements to promote favorable growth characteristics, e.g., trypsin,β-mercaptoethanol, and the like.

Procedures for maintaining mammalian cells in culture have beenextensively reported, and are known to those of skill in the art.General protocols are provided, e.g., in Freshney (1983) Culture ofAnimal Cells: Manual of Basic Technique, Alan R. Liss, New York; Paul(1975) Cell and Tissue Culture, 5^(th) ed., Livingston, Edinburgh; Adams(1980) Laboratory Techniques in Biochemistry and Molecular Biology-CellCulture for Biochemists, Work and Burdon (eds.) Elsevier, Amsterdam.Additional details regarding tissue culture procedures of particularinterest in the production of influenza virus in vitro include, e.g.,Merten et al. (1996) Production of influenza virus in cell cultures forvaccine preparation. In Cohen and Shafferman (eds) Novel Strategies inDesign and Production of Vaccines, which is incorporated herein in itsentirety. Additionally, variations in such procedures adapted to thepresent invention are readily determined through routineexperimentation.

Cells for production of influenza virus can be cultured inserum-containing or serum free medium. In some case, e.g., for thepreparation of purified viruses, it is desirable to grow the host cellsin serum free conditions. Cells can be cultured in small scale, e.g.,less than 25 ml medium, culture tubes or flasks or in large flasks withagitation, in rotator bottles, or on microcarrier beads (e.g.,DEAE-Dextran microcarrier beads, such as Dormacell, Pfeifer & Langen;Superbead, Flow Laboratories; styrene copolymer-tri-methylamine beads,such as Hillex, SoloHill, Ann Arbor) in flasks, bottles or reactorcultures. Microcarrier beads are small spheres (in the range of 100-200microns in diameter) that provide a large surface area for adherent cellgrowth per volume of cell culture. For example a single liter of mediumcan include more than 20 million microcarrier beads providing greaterthan 8000 square centimeters of growth surface. For commercialproduction of viruses, e.g., for vaccine production, it is oftendesirable to culture the cells in a bioreactor or fermenter. Bioreactorsare available in volumes from under 1 liter to in excess of 100 liters,e.g., Cyto3 Bioreactor (Osmonics, Minnetonka, Minn.); NBS bioreactors(New Brunswick Scientific, Edison, N.J.); laboratory and commercialscale bioreactors from B. Braun Biotech International (B. Braun Biotech,Melsungen, Germany).

Regardless of the culture volume, in the context of the presentinvention, the cultures can be maintained at a temperature less than orequal to 35° C., to insure efficient recovery of recombinant and/orreassortant influenza virus, particularly cold-adapted, temperaturesensitive, attenuated recombinant and/or reassortant influenza virus.For example, the cells are cultured at a temperature between about 32°C. and 35° C., typically at a temperature between about 32° C. and about34° C., usually at about 33° C.

Typically, a regulator, e.g., a thermostat, or other device for sensingand maintaining the temperature of the cell culture system is employedto insure that the temperature does not exceed 35° C. during the periodof virus replication.

6.7 Recovery of Viruses

Viruses are typically recovered from the culture medium, in whichinfected (transfected) cells have been grown. Typically crude medium isclarified prior to concentration of influenza viruses. Common methodsinclude filtration, ultrafiltration, adsorption on barium sulfate andelution, and centrifugation. For example, crude medium from infectedcultures can first be clarified by centrifugation at, e.g., 1000-2000×gfor a time sufficient to remove cell debris and other large particulatematter, e.g., between 10 and 30 minutes. Alternatively, the medium isfiltered through a 0.8 μm cellulose acetate filter to remove intactcells and other large particulate matter. Optionally, the clarifiedmedium supernatant is then centrifuged to pellet the influenza viruses,e.g., at 15,000×g, for approximately 3-5 hours. Following resuspensionof the virus pellet in an appropriate buffer, such as STE (0.01 MTris-HCl; 0.15 M NaCl; 0.0001 M EDTA) or phosphate buffered saline (PBS)at pH 7.4, the virus is concentrated by density gradient centrifugationon sucrose (60%-12%) or potassium tartrate (50%-10%). Either continuousor step gradients, e.g., a sucrose gradient between 12% and 60% in four12% steps, are suitable. The gradients are centrifuged at a speed, andfor a time, sufficient for the viruses to concentrate into a visibleband for recovery. Alternatively, and for most large scale commercialapplications, virus is elutriated from density gradients using azonal-centrifuge rotor operating in continuous mode. Additional detailssufficient to guide one of skill through the preparation of influenzaviruses from tissue culture are provided, e.g., in Furminger. VaccineProduction, in Nicholson et al. (eds) Textbook of Influenza pp.324-332;Merten et al. (1996) Production of influenza virus in cell cultures forvaccine preparation, in Cohen & Shafferman (eds) Novel Strategies inDesign and Production of Vaccines pp. 141-151, and U.S. Pat. No.5,690,937, U.S. publication application nos. 20040265987, 20050266026and 20050158342, which are incorporated by reference herein. If desired,the recovered viruses can be stored at −80° C. in the presence ofsucrose-phosphate-glutamate (SPG) as a stabilizer.

6.8 Influenza Viruses

The genome of influenza viruses is composed of eight segments of linear(−) strand ribonucleic acid (RNA), encoding the immunogenichemagglutinin (HA) and neuraminidase (NA) proteins, and six internalcore polypeptides: the nucleocapsid nucleoprotein (NP); matrix proteins(M); non-structural proteins (NS); and 3 RNA polymerase (PA, PB1, PB2)proteins. During replication, the genomic viral RNA is transcribed into(+) strand messenger RNA and (−) strand genomic cRNA in the nucleus ofthe host cell. Each of the eight genomic segments is packaged intoribonucleoprotein complexes that contain, in addition to the RNA, NP anda polymerase complex (PB1, PB2, and PA).

Influenza viruses which may be produced by the processes of theinvention in the MDCK cells of the invention include but are not limitedto, reassortant viruses that incorporate selected hemagglutinin and/orneuraminidase antigens in the context of an approved attenuated,temperature sensitive master strain. For example, viruses can comprisemaster strains that are one or more of, e.g., temperature-sensitive(ts), cold-adapted (ca), or an attenuated (att) (e.g., A/Ann Arbor/6/60,B/Ann Arbor/1/66, PR8, B/Leningrad/14/17/55, B/14/5/1, B/USSR/60/69,B/Leningrad/179/86, B/Leningrad/14/55, B/England/2608/76,A/PuertoRico/8/34 (i.e., PR8), etc. or antigenic variants or derivativesthereof).

6.9 Influenza Virus Vaccines

Historically, influenza virus vaccines have been produced in embryonatedhens' eggs using strains of virus selected based on empiricalpredictions of relevant strains. More recently, reassortant viruses havebeen produced that incorporate selected hemagglutinin and neuraminidaseantigens in the context of an approved attenuated, temperature sensitivemaster strain. Following culture of the virus through multiple passagesin hens' eggs, influenza viruses are recovered and, optionally,inactivated, e.g., using formaldehyde and/or β-propiolactone. However,production of influenza vaccine in this manner has several significantdrawbacks. Contaminants remaining from the hens' eggs are highlyantigenic, pyrogenic, and frequently result in significant side effectsupon administration. More importantly, strains designated for productionmust be selected and distributed, typically months in advance of thenext flu season to allow time for production and inactivation ofinfluenza vaccine. Attempts at producing recombinant and reassortantvaccines in cell culture have been hampered by the inability of any ofthe strains approved for vaccine production to grow efficiently understandard cell culture conditions.

The present invention provides a vector system, compositions, andmethods for producing recombinant and reassortant viruses in culturewhich make it possible to rapidly produce vaccines corresponding to oneor many selected antigenic strains of virus. In particular, conditionsand strains are provided that result in efficient production of virusesfrom a multi plasmid system in cell culture. Optionally, if desired, theviruses can be further amplified in hens' eggs or cell cultures thatdiffer from the cultures used to rescue the virus.

For example, it has not been possible to grow the influenza B masterstrain B/Ann Arbor/1/66 under standard cell culture conditions, e.g., at37° C. In the methods of the present invention, multiple plasmids, eachincorporating a segment of an influenza virus genome are introduced intosuitable cells, and maintained in culture at a temperature less than orequal to 35° C. Typically, the cultures are maintained at between about32° C. and 35° C., preferably between about 32° C. and about 34° C.,e.g., at about 33° C.

Typically, the cultures are maintained in a system, such as a cellculture incubator, under controlled humidity and CO₂, at constanttemperature using a temperature regulator, such as a thermostat toinsure that the temperature does not exceed 35° C.

Reassortant influenza viruses can be readily obtained by introducing asubset of vectors comprising cDNA that encodes genomic segments of amaster influenza virus, in combination with complementary segmentsderived from strains of interest (e.g., antigenic variants of interest).Typically, the master strains are selected on the basis of desirableproperties relevant to vaccine administration. For example, for vaccineproduction, e.g., for production of a live attenuated vaccine, themaster donor virus strain may be selected for an attenuated phenotype,cold adaptation and/or temperature sensitivity. In this context,influenza A strain ca A/Ann Arbor/6/60; influenza B strain ca B/AnnArbor/1/66; or another strain selected for its desirable phenotypicproperties, e.g., an attenuated, cold adapted, and/or temperaturesensitive strain, are favorably selected as master donor strains.

In one embodiment, plasmids comprising cDNA encoding the six internalvRNA segments of the influenza master virus strain, (i.e., PB1, PB2, PA,NP, NB, M1, BM2, NS1 and NS2) are transfected into suitable host cellsin combination with cDNA encoding hemagglutinin and neuraminidase vRNAsegments from an antigenically desirable strain, e.g., a strainpredicted to cause significant local or global influenza infection.Following replication of the reassortant virus in cell culture atappropriate temperatures for efficient recovery, e.g., equal to or lessthan 35° C., such as between about 32° C. and 35° C., for examplebetween about 32° C. and about 34° C., or at about 33° C., reassortantviruses is recovered. Optionally, the recovered virus can be inactivatedusing a denaturing agent such as formaldehyde or β-propiolactone.

6.10 Methods and Compositions for Prophylactic Administration ofVaccines

Recombinant and reassortant viruses of the invention can be administeredprophylactically in an appropriate carrier or excipient to stimulate animmune response specific for one or more strains of influenza virus.Typically, the carrier or excipient is a pharmaceutically acceptablecarrier or excipient, such as sterile water, aqueous saline solution,aqueous buffered saline solutions, aqueous dextrose solutions, aqueousglycerol solutions, ethanol, allantoic fluid from uninfected hens' eggs(i.e., normal allantoic fluid “NAF”) or combinations thereof. Thepreparation of such solutions insuring sterility, pH, isotonicity, andstability is effected according to protocols established in the art.Generally, a carrier or excipient is selected to minimize allergic andother undesirable effects, and to suit the particular route ofadministration, e.g., subcutaneous, intramuscular, intranasal, etc.

Generally, the influenza viruses of the invention are administered in aquantity sufficient to stimulate an immune response specific for one ormore strains of influenza virus. Preferably, administration of theinfluenza viruses elicits a protective immune response. Dosages andmethods for eliciting a protective immune response against one or moreinfluenza strains are known to those of skill in the art. For example,inactivated influenza viruses are provided in the range of about 1-1000HID₅₀ (human infectious dose), i.e., about 10⁵-10⁸ pfu (plaque formingunits) per dose administered. Alternatively, about 10-50 μg, e.g., about15 μg HA is administered without an adjuvant, with smaller doses beingadministered with an adjuvant. Typically, the dose will be adjustedwithin this range based on, e.g., age, physical condition, body weight,sex, diet, time of administration, and other clinical factors. Theprophylactic vaccine formulation is systemically administered, e.g., bysubcutaneous or intramuscular injection using a needle and syringe, or aneedleless injection device. Alternatively, the vaccine formulation isadministered intranasally, either by drops, large particle aerosol(greater than about 10 microns), or spray into the upper respiratorytract. While any of the above routes of delivery results in a protectivesystemic immune response, intranasal administration confers the addedbenefit of eliciting mucosal immunity at the site of entry of theinfluenza virus. For intranasal administration, attenuated live virusvaccines are often preferred, e.g., an attenuated, cold adapted and/ortemperature sensitive recombinant or reassortant influenza virus. Whilestimulation of a protective immune response with a single dose ispreferred, additional dosages can be administered, by the same ordifferent route, to achieve the desired prophylactic effect.

Alternatively, an immune response can be stimulated by ex vivo or invivo targeting of dendritic cells with influenza viruses. For example,proliferating dendritic cells are exposed to viruses in a sufficientamount and for a sufficient period of time to permit capture of theinfluenza antigens by the dendritic cells. The cells are thentransferred into a subject to be vaccinated by standard intravenoustransplantation methods.

Optionally, the formulation for prophylactic administration of theinfluenza viruses, or subunits thereof, also contains one or moreadjuvants for enhancing the immune response to the influenza antigens.Suitable adjuvants include: saponin, mineral gels such as aluminumhydroxide, surface active substances such as lysolecithin, pluronicpolyols, polyanions, peptides, oil or hydrocarbon emulsions, bacilleCalmette-Guerin (BCG), Corynebacterium parvum, and the syntheticadjuvants QS-21 and MF59.

If desired, prophylactic vaccine administration of influenza viruses canbe performed in conjunction with administration of one or moreimmunostimulatory molecules. Immunostimulatory molecules include variouscytokines, lymphokines and chemokines with immunostimulatory,immunopotentiating, and pro-inflammatory activities, such asinterleukins (e.g., IL-1, IL-2, IL-3, IL-4, IL-12, IL-13); growthfactors (e.g., granulocyte-macrophage (GM)-colony stimulating factor(CSF)); and other immunostimulatory molecules, such as macrophageinflammatory factor, Flt3 ligand, B7.1; B7.2, etc. The immunostimulatorymolecules can be administered in the same formulation as the influenzaviruses, or can be administered separately. Either the protein or anexpression vector encoding the protein can be administered to produce animmunostimulatory effect.

In another embodiment, the vectors of the invention including influenzagenome segments can be employed to introduce heterologous nucleic acidsinto a host organism or host cell, such as a mammalian cell, e.g., cellsderived from a human subject, in combination with a suitablepharmaceutical carrier or excipient as described above. Typically, theheterologous nucleic acid is inserted into a non-essential region of agene or gene segment, e.g., the M gene of segment 7. The heterologouspolynucleotide sequence can encode a polypeptide or peptide, or an RNAsuch as an antisense RNA or ribozyme. The heterologous nucleic acid isthen introduced into a host or host cells by producing recombinantviruses incorporating the heterologous nucleic, and the viruses areadministered as described above. In one embodiment, the heterologouspolynucleotide sequence is not derived from an influenza virus.

Alternatively, a vector of the invention including a heterologousnucleic acid can be introduced and expressed in a host cells byco-transfecting the vector into a cell infected with an influenza virus.Optionally, the cells are then returned or delivered to the subject,typically to the site from which they were obtained. In someapplications, the cells are grafted onto a tissue, organ, or system site(as described above) of interest, using established cell transfer orgrafting procedures. For example, stem cells of the hematopoieticlineage, such as bone marrow, cord blood, or peripheral blood derivedhematopoietic stem cells can be delivered to a subject using standarddelivery or transfusion techniques.

Alternatively, the viruses comprising a heterologous nucleic acid can bedelivered to the cells of a subject in vivo. Typically, such methodsinvolve the administration of vector particles to a target cellpopulation (e.g., blood cells, skin cells, liver cells, neural(including brain) cells, kidney cells, uterine cells, muscle cells,intestinal cells, cervical cells, vaginal cells, prostate cells, etc.,as well as tumor cells derived from a variety of cells, tissues and/ororgans. Administration can be either systemic, e.g., by intravenousadministration of viral particles, or by delivering the viral particlesdirectly to a site or sites of interest by a variety of methods,including injection (e.g., using a needle or syringe), needlelessvaccine delivery, topical administration, or pushing into a tissue,organ or skin site. For example, the viral vector particles can bedelivered by inhalation, orally, intravenously, subcutaneously,subdermally, intradermally, intramuscularly, intraperitoneally,intrathecally, by vaginal or rectal administration, or by placing theviral particles within a cavity or other site of the body, e.g., duringsurgery.

The above described methods are useful for therapeutically and/orprophylactically treating a disease or disorder by introducing a vectorof the invention comprising a heterologous polynucleotide encoding atherapeutically or prophylactically effective polypeptide (or peptide)or RNA (e.g., an antisense RNA or ribozyme) into a population of targetcells in vitro, ex vivo or in vivo. Typically, the polynucleotideencoding the polypeptide (or peptide), or RNA, of interest is operablylinked to appropriate regulatory sequences as described above in thesections entitled “Expression Vectors” and “Additional ExpressionElements.” Optionally, more than one heterologous coding sequence isincorporated into a single vector or virus. For example, in addition toa polynucleotide encoding a therapeutically or prophylactically activepolypeptide or RNA, the vector can also include additional therapeuticor prophylactic polypeptides, e.g., antigens, co-stimulatory molecules,cytokines, antibodies, etc., and/or markers, and the like.

In one embodiment, the invention provides compositions comprisingreassortant and recombinant viruses of the invention (or portionsthereof) that have been treated with an agent such as benzonase, toeliminate potential oncogenes. Accordingly, an oncogene-free vaccinecomposition is specifically included within the embodiments of theinvention.

The methods and vectors of the present invention can be used totherapeutically or prophylactically treat a wide variety of disorders,including genetic and acquired disorders, e.g., as vaccines forinfectious diseases, due to viruses, bacteria, and the like.

6.11 Kits

To facilitate use of the vectors and vector systems of the invention,any of the vectors, e.g., consensus influenza virus plasmids, variantinfluenza polypeptide plasmids, influenza polypeptide library plasmids,etc., and additional components, such as, buffer, cells, culture medium,useful for packaging and infection of influenza viruses for experimentalor therapeutic purposes, can be packaged in the form of a kit.Typically, the kit contains, in addition to the above components,additional materials which can include, e.g., instructions forperforming the methods of the invention, packaging material, and acontainer.

6.12 Manipulation of Viral Nucleic Acids and Proteins

In the context of the invention, nucleic acids comprising canine RNA polI regulatory sequences or other nucleic acids of the invention,expression vectors, influenza virus nucleic acids and/or proteins andthe like are manipulated according to well known molecular biologytechniques. Detailed protocols for numerous such procedures, includingamplification, cloning, mutagenesis, transformation, and the like, aredescribed in, e.g., in Ausubel et al. Current Protocols in MolecularBiology (supplemented through 2000) John Wiley & Sons, New York(“Ausubel”); Sambrook et al. Molecular Cloning—A Laboratory Manual (2ndEd.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.,1989 (“Sambrook”), and Berger and Kimmel Guide to Molecular CloningTechniques, Methods in Enzymology volume 152 Academic Press, Inc., SanDiego, Calif. (“Berger”).

In addition to the above references, protocols for in vitroamplification techniques, such as the polymerase chain reaction (PCR),the ligase chain reaction (LCR), Qβ-replicase amplification, and otherRNA polymerase mediated techniques (e.g., NASBA), useful e.g., foramplifying cDNA probes of the invention, are found in Mullis et al.(1987) U.S. Pat. No. 4,683,202; PCR Protocols A Guide to Methods andApplications (Innis et al. eds) Academic Press Inc. San Diego, Calif.(1990) (“Innis”); Arnheim and Levinson (1990) C&EN 36; The Journal OfNIH Research (1991) 3:81; Kwoh et al. (1989) Proc Natl Acad Sci USA 86,1173; Guatelli et al. (1990) Proc Natl Acad Sci USA 87:1874; Lomell etal. (1989) J Clin Chem 35:1826; Landegren et al. (1988) Science241:1077; Van Brunt (1990) Biotechnology 8:291; Wu and Wallace (1989)Gene 4: 560; Barringer et al. (1 990) Gene 89:117, and Sooknanan andMalek (1995) Biotechnology 13:563. Additional methods, useful forcloning nucleic acids in the context of the present invention, includeWallace et al. U.S. Pat. No. 5,426,039. Improved methods of amplifyinglarge nucleic acids by PCR are summarized in Cheng et al. (1994) Nature369:684 and the references therein.

Certain polynucleotides of the invention, e.g., oligonucleotides can besynthesized utilizing various solid-phase strategies includingmononucleotide- and/or trinucleotide-based phosphoramidite couplingchemistry. For example, nucleic acid sequences can be synthesized by thesequential addition of activated monomers and/or trimers to anelongating polynucleotide chain. See e.g., Caruthers, M. H. et al.(1992) Meth Enzymol 211:3.

In lieu of synthesizing the desired sequences, essentially any nucleicacid can be custom ordered from any of a variety of commercial sources,such as The Midland Certified Reagent Company (mcrc@oligos.com), TheGreat American Gene Company (www.genco.com), ExpressGen, Inc.(www.expressgen.com), Operon Technologies, Inc. (www.operon.com), andmany others.

In addition, substitutions of selected amino acid residues in viralpolypeptides can be accomplished by, e.g., site directed mutagenesis.For example, viral polypeptides with amino acid substitutionsfunctionally correlated with desirable phenotypic characteristic, e.g.,an attenuated phenotype, cold adaptation, temperature sensitivity, canbe produced by introducing specific mutations into a viral nucleic acidsegment encoding the polypeptide. Methods for site directed mutagenesisare well known in the art, and described, e.g., in Ausubel, Sambrook,and Berger, supra. Numerous kits for performing site directedmutagenesis are commercially available, e.g., the Chameleon SiteDirected Mutagenesis Kit (Stratagene, La Jolla), and can be usedaccording to the manufacturers instructions to introduce, e.g., one ormore amino acid substitutions, into a genome segment encoding ainfluenza A or B polypeptide, respectively.

6.13 Other Viruses

The nucleic acids, vectors, and methods of the present invention canalso be used for expression and purification of other recombinantviruses. The following discussion provides guidance for considerationsimportant in adapting the vectors for use with other such viruses.

If the target virus comprises a positive strand, segmented RNA genome, acanine RNA pol I promoter is, preferably, located upstream of the cDNAin the inner transcription unit (unidirectional system). In thisembodiment, positive strand RNA is generated for direct incorporationinto new viruses. However, embodiments wherein target viruses comprisenegative strand, segmented RNA genomes are produced using theunidirectional system are within the scope of the invention.

If the target virus comprises a negative strand, segmented RNA genome,the canine RNA pol I promoter is, preferably, located downstream of thecDNA in the inner transcription unit (bidirectional system). In thisembodiment, negative stranded RNA is generated for direct incorporationinto new viruses. Embodiments wherein target viruses comprising positivestranded, segmented RNA genomes are produced with the bidirectionalsystem are within the scope of the invention.

The present invention may also be used to produce viruses comprisinginfectious or noninfectious unsegmented RNA genomes (single stranded ordouble stranded). In general, simple introduction of infectious viralgenomic RNA into a host cell is sufficient to cause initiation of theviral life cycle within the cell and the eventual production of completeviruses. For example, simple introduction of picomaviral genomic RNAinto a host cell is sufficient to cause generation of completepicomaviruses. Initiation of the life cycle of a virus comprisinguninfectious genomic RNA, typically, requires the additionalintroduction of other viral proteins which are usually carried withinthe viral particle along with the genome. For example, parainfluenzavirus III carries an RNA dependent RNA polymerase whose presence isrequired within a newly infected host cell for initiation of viralgenomic RNA replication and transcription of viral mRNAs; in the absenceof the polymerase, parainfluenza III genomic RNA is not infectious. Inembodiments of the present invention wherein viruses comprisinginfectious, unsegmented genomic RNAs are generated, simple introductionof a dual expression plasmid of the invention, carrying a nucleic acidincluding the viral genome, into a suitable host cell is sufficient tocause generation of complete viruses. In embodiments wherein virusescomprising uninfectious unsegmented genomic RNA are generated,additional expression plasmids may also have to be introduced into ahost cell along with the dual expression plasmid carrying the viralgenome. The additional plasmid should express the protein(s) requiredfor initiation of the viral life cycle which are normally introducedinto a host cell upon infection (e.g., RNA dependent RNA polymerases).

In embodiments wherein picomavirus, which comprising an infectious,unsegmented RNA genome, is produced, cDNA comprising the complete viralgenome is inserted into a dual promoter expression plasmid of theinvention. An upstream promoter in an outer transcription unit,preferably, a pol II promoter, directs production of a positive strandmRNA comprising the complete viral genome—a polyprotein is translatedfrom the mRNA and individual proteins are cleaved and liberated from thepolyprotein (e.g., by a protease within the polyprotein). Since theviral genome comprises positive strand RNA, a second upstream promoterin an inner transcription unit (unidirectional system), preferablycanine RNA pol I, directs production of a positive stranded copy of thegenome. If the viral genome comprised negative strand RNA, a seconddownstream promoter, in an inner transcription unit (bidirectionalsystem), preferably canine RNA pol I, would direct production of anegative stranded copy of the genome. Embodiments wherein negativestranded, unsegmented RNA viruses are produced using the unidirectionalsystem are within the scope of the invention. Similarly, embodimentswherein positive stranded, unsegmented RNA viruses are produced usingthe bidirectional system are within the scope of the invention.

Viruses comprising uninfectious, unsegmented RNA genomes wherein apolyprotein is not produced can also be generated with the presentinvention. For example, the present system may be used to producerhabdoviridae viruses or paramyxoviridae viruses, preferablyparainfluenza virus III, whose life cycle normally includes productionof multiple monocistronic mRNAs from genomic, negative strand RNA by avirally derived RNA dependent RNA polymerase; individual proteins areexpressed from the monocistronic mRNAs. In these embodiments, an outertranscription unit comprising a promoter, preferably a pol II promoter,directs production of a positive strand, polycistronic copy of the viralgenome from which, generally, only the first gene (NP) is translated.Additionally, an inner transcription unit comprising a promoter,preferably a canine pol I promoter, directs expression of an RNA copy ofthe genome for incorporation into new viruses. Since the parainfluenzaIII viral genome comprises negative stranded RNA, the promoter of theinner transcription unit is preferably located downstream of the cDNA(bidirectional system). If the viral genome comprises positive strandRNA, the promoter of the inner transcription unit is preferably locatedupstream of the cDNA (unidirectional system). Embodiments whereinviruses comprising a positive stranded RNA genome are produced using thebidirectional system and embodiments wherein viruses comprising anegative stranded RNA genome are produced using the unidirectionalsystem are within the scope of the invention. Additional viral proteins(other than the protein expressed from the polycistronic mRNA) arerequired for viral transcription and replication (L and P), and theseproteins are provided individually on separate expression plasmids.

The invention may also include embodiments wherein viruses comprisingdouble stranded, segmented RNA genomes are generated. In theseembodiments, a plasmid comprising each gene in the target viral genomecan be inserted into a dual promoter expression plasmid of theinvention. The plasmid may be either a unidirectional plasmid or abidirectional plasmid. A promoter in an outer transcriptional unit,preferably a pol II promoter, directs expression of an mRNA transcriptof each gene which is translated into the encoded protein. A promoter inan inner transcription unit, preferably a canine pol I promoter, directstranscription of either a positive strand (unidirectional system) or anegative strand (bidirectional system). Subsequently, the first strandwhich is produced may act as a template for production of thecomplementary strand by viral RNA polymerase. The resulting doublestranded RNA product is incorporated into new viruses.

7. SPECIFIC EMBODIMENTS

1. An isolated nucleic acid comprising a canine RNA polymerase Iregulatory sequence.

2. The nucleic acid of embodiment 1, wherein the regulatory sequence isa promoter.

3. The nucleic acid of embodiment 1, wherein the regulatory sequence isan enhancer.

4. The nucleic acid of embodiment 1, wherein the regulatory sequence isboth an enhancer and a promoter.

5. The nucleic acid of embodiment 1, wherein the RNA polymeraseregulatory sequence comprises nucleotides 1 to 1804 of SEQ ID NO: 1 or afunctionally active fragment thereof.

6. The nucleic acid of embodiment 1, 2, 3, 4, or 5, wherein theregulatory sequence is operably linked to cDNA encoding anegative-strand viral genomic RNA or the corresponding cRNA.

7. The nucleic acid of embodiment 6, wherein the negative-strand viralgenomic RNA is an influenza genomic RNA.

8. The nucleic acid of embodiment 6 or 7, wherein the nucleic acidfurther comprises a transcription termination sequence.

9. An expression vector comprising the nucleic acid of embodiment 1, 2,3, 4, 5, 6, 7, or 8.

10. The expression vector of embodiment 9, wherein the expression vectorcomprises a bacterial origin of replication.

11. The expression vector of embodiment 9, wherein the expression vectorcomprises a selectable marker that can be selected in a prokaryoticcell.

12. The expression vector of embodiment 9, wherein the expression vectorcomprises a selectable marker that can be selected in a eukaryotic cell.

13. The expression vector of embodiment 9, wherein the expression vectorcomprises a multiple cloning site.

14. The expression vector of embodiment 13, wherein the multiple cloningsite is oriented relative to the canine RNA polymerase I regulatorysequence to allow expression of a coding sequence introduced into themultiple cloning site from the regulatory sequence.

15. A method for producing an influenza genomic RNA, comprisingtranscribing the nucleic acid of embodiment 7, thereby producing aninfluenza genomic RNA.

16. A method for producing a recombinant influenza virus, comprisingculturing a canine cell comprising the expression vector of embodiment9, 10, 11, 12 13, or 14 and one or more expression vectors that expressan mRNA encoding one or more influenza polypeptide selected from thegroup consisting of: PB2, PB1, PA, HA, NP, NA, M1, M2, NS1, and NS2; andisolating the recombinant influenza virus.

17. The method of embodiment 16, wherein a helper virus is used.

18. The method of embodiment 16, wherein influenza virus produced isinfectious.

19. The method of embodiment 16, 17 or 18, wherein the method results inthe production of at least 1×10³ PFU/ml influenza viruses.

20. A cell comprising the nucleic acid of embodiment 1, 2, 3, 4, 5, 6, 7or 8.

21. A cell comprising the expression vector of embodiment 9, 10, 11, 12,13 or 14.

22. The cell of embodiment 20 or 21, wherein the cell is a canine cell.

23. The canine cell of embodiment 22, wherein the canine cell is akidney cell.

24. The canine kidney cell of embodiment 23, wherein the canine kidneycell is an MDCK cell.

25. A method for generating in cultured canine cells a recombinantsegmented negative-strand RNA virus having greater than 3 genomic vRNAsegments, said method comprising: (a) introducing into a population ofcanine cells a first set of expression vectors capable of expressing insaid cells genomic vRNA segments to provide the complete genomic vRNAsegments of said virus; (b) introducing into said cells a second set ofexpression vectors capable of expressing mRNA encoding one or morepolypeptides of said virus; and (c) culturing said cells whereby viralparticles are produced.

26. The method of embodiment 25, wherein infectious influenza viralparticles are produced.

27. The method of embodiment 25 or 26, wherein helper virus is used.

28. A method for generating in cultured canine cells infectiousinfluenza viral particles, said method comprising: (a) introducing intoa population of canine cells a set of expression vectors capable ofexpressing in said cells i) genomic vRNA segments to provide thecomplete genomic vRNA segments of said virus and (ii) mRNA encoding oneor more polypeptides of said virus; (b) culturing said cells wherebysaid viral particles are produced.

29. A method of transcribing a vRNA segment of an influenza virus,comprising contacting a canine pol I polymerase polypeptide with apolynucleotide comprising a nucleic acid selected from the groupconsisting of: SEQ ID Nos 1-19, wherein said nucleic acid is operablylinked to a cDNA molecule encoding said vRNA segment of said negativestrand virus; and isolating a transcribed vRNA segment.

30. The method of embodiment 29, wherein the vRNA is transcribed in ahost cell.

31. The method of embodiment 16, 17, 18, 19, 25, 26, 27 or 28, whereineach expression vector is on a separate plasmid.

32. A composition comprising a plurality of vectors, wherein theplurality of vectors comprise a vector comprising a canine pol Ipromoter operably linked to an influenza virus PA cDNA linked to atranscription termination sequence, a vector comprising a canine pol Ipromoter operably linked to an influenza virus PB1 cDNA linked to atranscription termination sequence, a vector comprising a canine pol Ipromoter operably linked to an influenza virus PB2 cDNA linked to atranscription termination sequence, a vector comprising a canine pol Ipromoter operably linked to an influenza virus HA cDNA linked to atranscription termination sequence, a vector comprising a canine pol Ipromoter operably linked to an influenza virus NP cDNA linked to atranscription termination sequence, a vector comprising a canine pol Ipromoter operably linked to an influenza virus NA cDNA linked to atranscription termination sequence, a vector comprising a canine pol Ipromoter operably linked to an influenza virus M cDNA linked to atranscription termination sequence, and a vector comprising a canine polI promoter operably linked to an influenza virus NS cDNA linked to atranscription termination sequence.

33. The composition of embodiment 32 further comprising one or moreexpression vectors that express an mRNA encoding one or more influenzapolypeptide selected from the group consisting of: PB2, PB1, PA, HA, NP,NA, M1, M2, NS1, and NS2.

34. A host cell comprising the composition of embodiments 32 or 33.

35. A vaccine comprising a virus produced by the method of embodiment16, 17, 18, 19, 25,26,27 or 28.

36. A vaccine comprising an immunogenic composition prepared from avirus produced from the method of embodiment 16, 17, 18, 19,25, 26 27 or28.

37. The composition of embodiment 35 or 36, wherein each expressionvector is on a separate plasmid.

8. EXAMPLES

The following examples serve, merely to illustrate the invention and arenot intended to limit the invention in any way.

8.1 Example 1 Growth of Influenza Strains in MDCK Cells

This example describes characterization of several cell lines forculturing influenza. Several different cell lines and primary cells wereevaluated for the production of both wild-type (wt) and geneticreassortants derived from laboratory adapted, e.g., cold adapted (ca),influenza strains, type A and type B, including MRC-5, WI-38, FRhL-2,PerC6, 293, NIH 3T3, CEF, CEK, DF-1, Vero, and MDCK. While many of thecell types supported the replication of some cold-adapted influenzastrains to a limited extent, only MDCK consistently produced high titersof both type A and type B viruses. For example, PerC6 cells were foundto support the replication of certain wt and ca type B viruses to asimilar level as that seen in MDCK cells although the growth kineticsare different (see FIG. 1). In contrast, PerC6 was unable to support thereplication of a number of ca type A viruses. FIG. 2 shows the growthcurves for wt and ca A/Sydney/05/97 and A/Beijing/262/95 viruses. Inboth cases the ca strain does not replicate well in PerC6 cells.Likewise, FIG. 3 shows the growth curves for wt and ca A/Ann Arbor/6/60demonstrating that the ca strain does not replicate efficiently in PerC6cells and the replication of wt A/Ann Arbor/6/60 is not as robust as inMDCK cells. Real time PCR analysis of influenza virus replication inPerC6 cells showed that viral RNA (vRNA) of both the ca and wt Ainfluenza virus strains increased during the first 24 hours postinfection however only the wt strains continued to increase out to 120hours, the ca strains did not. In contrast, both wt and ca vRNAincreased and reached plateau at day 3 in MDCK cells. See FIG. 4.

The MDCK cells were also tested for their ability to support replicationof a potential pandemic vaccine, ca A/Vietnam/1203/2004. MDCK cells wereinfected at a low multiplicity of infection with ca A/Vietnam/1203/2004and virus in the supernatant was quantified at various times postinfection. By 48 hours post infection, the titers of caA/Vietnam/1203/2004 reached approximately 8 logio TCID₅₀/mL and remainedstable for the next 3 to 4 days. See FIG. 5.

In the experiments, MDCK cells obtained from the ATCC (Accession No.CCL-34) were expanded a limited number of times in either mediacontaining 10% fetal bovine serum sourced from the United States or inan appropriate serum free media (e.g., SFMV 100) to produce pre-mastercell stocks for initial characterization studies. Appropriate serum-freemedia are described in U.S. Provisional Application No. 60/638,166,filed Dec. 23, 2004; U.S. Provisional Application No. 60/641,139, filedJan. 5, 2005; and U.S. application Ser. No. 11/304,589 filed Dec. 16,2005, each of which is hereby incorporated by reference in its entirety.Cells were readily grown in both types of media and both stocks of cellssupported the replication of cold-adapted vaccine strains and pandemicstrains as shown in Table 1, below, and in FIG. 5, respectively. TABLE 1Comparison of productivity of cold-adapted influenza strains in serumand serum free grown MDCK cells. TCID₅₀/mL (log₁₀) Virus strain (6:2reassortant) MDCK with serum MDCK w/out serum A/New Caledonia/20/99 8.17.8 (H1N1) A/Panama/20/99 (H3N2) 6.8 6.4 A/Sydney/05/97 (H3N2) 7.0 6.5B/Brisbane/32/2002 7.2 7.5 B/Hong Kong/330/2001 7.2 7.4B/Victoria/504/2000 6.9 7.5

To investigate the gene segments responsible for the restricted growthin PerC6 cells the eight-plasmid rescue technique was employed togenerate a 7:1 reassortant for each gene segment of the influenzaA/AA/6/60 strain. See, e.g., U.S. Pat. No. 6,951,754 for arepresentative description of the eight-plasmid influenza rescue system.FIG. 6 shows a schematic diagram and the naming strategy for each 7:1reassortant. The resulting reassortants were then assayed for theirability to replicate in PerC6 cells. See FIG. 7. The growth restrictionphenotype appears to map to the PB2 and PB1 gene segments. Fine detailmapping of the exact location responsible for this phenotype can beperformed using methods well know in the art. For example, sequencecomparison of wt and ca strains in the identified gene segments willallow for the identification of specific differences which can then beback mutated in either a wt or ca strain. Such mutants are then analyzedfor their ability to grow in PerC6 cells. Any mutation that eitherprevents growth of a wt strain or allows growth of a ca strain isidentified as one that contributes to the growth restriction phenotype.

8.2 Example 2 Tumorigenicity of MDCK Cell Lines

The potential tumorigenicity of the two pre-master cell stocks of MDCKcells, one grown in media containing serum and the other in serum freemedia, were evaluated in the athymic nude mouse model at a stage thatwould represent 5 cell passages after that expected to be used forvaccine production. To evaluate tumorigenicity, 10⁷ cells were injectedsubcutaneously into groups of 10 mice and after 84 days the animals weresacrificed and examined. Neoplasias were observed in six of the 10animals inoculated with the cells passaged in serum free media. Incontrast, there was no evidence of neoplasia in any of the animalsinoculated with cells passaged in media supplemented with 10% fetalbovine serum; although some fibrosarcomas were observed at the site ofinoculation, cells passaged in serum were not tumorigenic as shown inTable 2. TABLE 2 Tumorigenicity and Karyology of MDCK cells passed intwo different media Serum free 10% Serum Passage 4 Passage 20 Passage 4Passage 20 Tumorigenicity ND Neoplasias ND No neoplasias. notedFibrosarcomas at injection site Estimated TP₅₀* ND ˜10⁷ ND Not estimable(no animals with (6/10) (>10⁷) tumors/total (0/10) animals) Karyology78; Large 78; Large 78; Few cells 78; Few cells Median number;distribution of distribution of with with anomalous comments cells withcells with anomalous chromosome chromosome chromosome chromosome number(70 to number of52 number of 52-82 number (70 to 82) to 82 82)*TP₅₀: Number of cells required to induce tumors in 50% of animalsND: Not done

As shown in Table 2, karyotype analyses were also performed on these twopremaster cell stocks at both the fourth and twentieth passage in theirrespective media. The non-tumorigenic cells passaged in 10% FCS had amedian number of 78 metaphase chromosomes with relatively limiteddistribution of cells with other chromosome numbers (70 to 82). Whilethe cells passaged in serum free media also had a median number of 78metaphase chromosomes, significantly more cells were observed with ananeuploid chromosome number ranging from 52 to 82 metaphase chromosomes.In both cases, the karyology did not change following passage.

8.3 Example 3 Adapting MDCK Cells to Grow in Serum Free Media

MDCK cells from the ATCC are passaged in media containing gammairradiated FBS. These cells are then passaged a limited number of timesin a serum free media formulation chosen to support cell bankproduction. Serum free media are described in U.S. ProvisionalApplication Nos. 60/638,166 and 60/641,139, and U.S. patent applicationSer. No. 11/304,589. These additional passages maybe performed at either37° C. or 33° C. Passage of MDCK cells in three media containingplant-derived supplements rather than serum yielded cells withkaryotypes similar to that of MDCK cells passaged in FCS containingmedia (data not shown).

8.4 Example 4 Cloning of MDCK Cells

Cells were biologically cloned through limiting dilution in order toensure that the production cells are derived from a unique geneticconstellation. Clones were screened for various phenotypic propertiesincluding doubling time and relative tumorigenicity, as well as viralproduction. In an initial proof of concept experiment, fifty-four MDCKclones were obtained in media containing FCS. These clones were passagedand each was infected with a low multiplicity of infection of ca A/NewCaledonia/20/99. Several days after infection, the supernatant wasremoved and the quantity of virus in the supernatant was measured byTCID₅₀. A minority of the clones produced relatively high titers ofvirus, greater than was produced in the non-cloned parental cells.Clones with superior biological and physiological properties are used toestablish a Master Cell Bank (MCB) as described below.

8.5 Example 5 Testing and Characterization of a Master Cell Bank

The MCB is extensively tested to ensure that there is no evidence ofadventitious agents. For example, one or more of several PCR and/orantibody-specific tests for available viral agents are conducted, asshown in Table 3, below. TABLE 3 Testing regimen for the MCB Generaltests PCR*/Ab specific Sterility AAV Types 1&2 Mycoplasma HCMVAdventitious agents in vitro (multiple EBV cell lines) Adventitiousagents in vivo HSV PERT Hepatitis B, C & E Co-cultivation HHV 6, 7 & 8Karyology HIV 1&2 Electron microscopy HPV Tumorigenicity intact cells(TP₅₀) HTLV I & II Oncogenicity of cellular DNA Polyoma (BK and JCviruses) Oncogenicity of cellular lysate Circovirus Bovine viruses per9CFR Canine Parvovirus Porcine viruses per 9CFR Canine distemperAdenovirus SV40

8.6 Example 6 Preclinical Characterization of Cell Culture-DerivedInfluenza Virus

This example describes characterization of influenza strains producedfrom cell culture as well as from eggs and compares the viruses producedfrom the systems. Generally, the influenza viruses are suitable for useas vaccines in humans, and have biological properties that make theviruses suitable for such use. In this example, the influenza virusesare cold-adapted (ca; have the ability to replicate efficiently at lowertemperatures), temperature sensitive (ts; have restricted replication invitro at higher temperatures), and attenuated (att; no detectablereplication in lung tissues of ferrets), and are referred to herein ascatsatt strains. The comparison includes: biochemical, antigenic, andgenetic evaluation (sequencing) of viral product; biological andbiochemical characterization of the virus following replication in humancells; replication in a permissive animal model; and immunogenicity in apermissive animal model.

8.6.1 Genetic, Biochemical and Antigenic Comparability

Ca ts att strains of type A/H1N1, A/H5N1, A/H3N2 and B replicated torelatively high titers in MDCK cells. In addition, passaging these ca tsatt strains in MDCK cells did not alter their genomic sequence. Three cats att strains, ca A/Sydney/05/97, ca A/Beijing/262/95, and ca B/AnnArbor/1/94 were passaged once or twice in MDCK cells and the entirecoding regions of all 6 internal genes were sequenced and compared tothe starting material. No nucleotide changes were observed,demonstrating that this passaging through this substrate did not changethe genetic composition of these strains. Further sequencecharacterizations is performed on different vaccine strains produced inMDCK cells under conditions that are expected to mimic the productionprocess including media composition, input dose (moi), temperature ofincubation and time of harvest. Based on the preliminary data, it isexpected that there will be no changes in the genomic sequence ofMDCK-produced virus.

Because the genome was genetically stable following passage in MDCKcell, the biological traits of the vaccine produced in eggs or MDCKcells are expected to be indistinguishable. However, the primary viralproduct from cell culture may have some subtle differences compared tothe egg based product, particularly with respect to post-translationalmodification of viral proteins including HA and NA, or composition oflipids in the viral membrane; both of which could potentially change theoverall physical properties of the virion. Preliminary preclinical dataon the antigenicity of cell culture produced and egg produced vaccinedemonstrated that there were no detectable differences in this importantparameter. Egg stocks of several vaccine strains were passaged throughMDCK cells and the antigenicity of both products was determined bymeasuring the HAI titers using reference antisera. As show in Table 4,all the HAI titers were within 2-fold of one another, indicating thatreplication of the vaccine in cells did not change the antigenicity ofthe vaccine compared to egg derived material. TABLE 4 HAI Titers ofstrains produced in eggs and MDCK cells HAI Titer MDCK Strain Eggderived derived A/Panama/20/99 256 256 A/Wuhan/359/95 1024 2048A/Wyoming/03/2003 512 1024 B/Jilin/20/2003 64 32 B/Hong Kong/330/01 6464 B/Jiangsu/10/2003 128 128

8.7 Example 7 Infection of Human Epithelial Cells in Culture

In one embodiment, to evaluate the biochemical, biological, andstructural similarities following replication of the MDCK and eggproduced vaccines in cells of human origin, vaccines may be passagedonce in relevant diploid human cells, such as normal human bronchialepithelial cells (NHBE). This passage will serve to mimic a singleinfection event in the human airway and then enable comparison of theprogeny virus, the virus that is ultimately responsible for eliciting aneffective immune response. Studies of the vaccines' hemagglutinin(binding and fusion) and neuraminidase activities can be measured onthese materials as well as other biochemical and structural studiesincluding electron microscopy, infectious to total particle ratios, andviral genome equivalents can be evaluated. Overall, these comparisonswill serve to demonstrate the comparability of the cell-derived vaccineto the effective and safe egg produced vaccine. A summary of analyticalstudies is summarized in Table 5. TABLE 5 Preclinical studies to comparecell and egg produced vaccines In vivo (ferrets) In vitro*Attenuation/Replication Virus binding Extent of replication in upperairway Hemagglutination titer Kinetics of replication in upper airwayBinding of different sialic acids Immunogenicity Physical propertiesCross-reactivity Morphology by EM Kinetics Infectious: Total particles(genomes) Infectivity Fusion activity Dose required for detectablereplication pH optimum Dose required for antibody response temperatureoptimum Genomic sequence Neuraminidase activity*Compare primary products and after one passage in human cells

8.8 Example 8 Preclinical Animal Models

The ferret is a robust animal model used to evaluate the attenuation andimmunogenicity of attenuated influenza vaccines and component vaccinestrains. The performance of cell-derived influenza strains produced fromthe MCB are compared to the same strains produced in eggs. Head to headcomparison of these materials in controlled studies enables a high levelof assurance of the comparability of these viral products.

In order to evaluate the ability of the two vaccines to infect orachieve a “take” in the ferret, animals are lightly anesthetized andinoculated intranasally with either the cell or egg produced viralpreparations. Nasal wash material is collected at several time pointsfollowing inoculation and the quantity of virus is evaluated by one ofseveral available methods in order to evaluate the kinetics and extentof viral replication in the animals' upper respiratory tract.Experiments are performed with a range of doses and include multiplestrains and different trivalent mixtures to generalize the relativeinfectivity of cell culture grown strains to egg produced strains. Thesesame studies are also used to evaluate the immunogenicity of theinfluenza strains, a property that is inherently linked to the abilityof the virus to initiate infection. Animals are bled and nasal washesare harvested at various points (weeks) post inoculation; thesespecimens are used to assess the serum antibody and nasal IgA responsesto infection. The culmination of these data, infectivity, serum antibodyand mucosal antibody responses, will be used to compare and evaluate therelative infectivity of the cell-produced vaccine to the egg producedvaccine. The most likely outcome is predicted to be that the cell andegg produced vaccine strains have similar infectivity andimmunogenicity. If the cell derived vaccine appeared to be moreinfective or more immunogenic than the egg-derived product, furtherstudies evaluating the possibility of lower dosage are performed.

A number of immunogenicity and replication studies are performed in theferret model to evaluate the cell culture-derived vaccines with a singleunit human dose. Infection with ca ts att strains generally elicitsstrong and rapid antibody responses in ferrets. In addition, individualca ts att strains are routinely tested and shown to express theattenuated (att) phenotype by replicating to relatively high titers inthe nasopharynx but to undetectable levels in the lung of these animals.The impact of cell culture growth on these biological traits is alsoassessed. However, it is unlikely that any differences will be seen,since the att phenotype is an integral part of the genetic compositionof these strains. The growth kinetics and crossreactivity of thesestrains is evaluated following administration of a single human dose inthese animals. This elicits serum antibodies that cross-react withmultiple strains within a genetic lineage; and it is expected that acell-derived vaccine will have the same capability.

These comparability evaluations should provide significant insight intopotential biochemical and/or biophysical differences of the primaryvirus product and demonstrate the impact of these epigenetic differenceson the performance of the ca ts att strains measured by first passagingthe virus in human cells or animal studies. Based on the sequenceinformation to date, there is no expected impact on the ca ts attstrains immunogenic performance resulting from production on MDCK cells.

Ferrets are a well document animal model for influenza and are usedroutinely to evaluate the attenuation phenotype and immunogenicity of cats att strains. In general, 8-10 week old animals are used to assessattenuation; typically study designs evaluate n=3-5 animals per test orcontrol group. Immunogenicity studies are evaluated in animals from 8weeks to 6 months of age and generally require n=3-5 animals per testarticle or control group. These numbers provide sufficient informationto obtain statistically valid or observationally important comparisonsbetween groups. During most studies Influenza-like signs may be noticed,but are not likely. Ferrets do not display signs of decrease in appetiteor weight, nasal or ocular discharge; observing signs of influenza-likeillness is a necessary part of the study and interventions such asanalgesics are not warranted. Other signs of discomfort, such as opensores or significant weight loss, would result in appropriatedisposition of the animal following discussion with the attendingveterinarian.

8.9 Example 9 Master Virus Seed (MVS) Development

Currently influenza vaccine strains are generated by co-infecting aviancells with a wild type virus and either the type A or type B MDV andisolating and screening the progeny for the desired 6:2 geneticconstellation. This process requires several passages of the virusthrough avian cell cultures and/or SPF eggs. Recently, plasmid rescuehas been introduced for producing influenza viral preparation. In thisprocess, Vero (African green monkey) cells from an extensively testedand characterized cell bank are electroporated with, e.g., 8 DNAplasmids, each containing a cDNA copy of one of the 8 influenza RNAsegments. Several days after electroporation the supernatant of theseelectroporated cells contains influenza virus. The supernatants are theninoculated into SPF eggs to amplify and biologically clone the vaccinestrain. Both of these procedures result in a vaccine strain that isinoculated into SPF eggs to produce the MVS. While plasmid rescue hasseveral advantages including more reliable timing, more geneticallyaccurate gene segments and less potential contamination withadventitious agents from the wild type isolate, individual MVS'sgenerated by these two methods are indistinguishable from one anotherand can be used to initiate bulk vaccine production. Using the methodsand composition of the invention, this method is adapted to use MDCKcells instead of the Vero cells for plasmid rescue.

Final amplification of the vaccine strains is conducted in cells derivedfrom the MDCK cell banks. This final amplification can be achievablewith small-scale cultures (<20 L) of MDCK cells. The supernatant fromthese cells is collected, concentrated and characterized/tested toproduce the MVS.

8.10 Example 10 Cloning of Canine RNA Pol I Regulatory Sequences

This example describes cloning of the canine 18S ribosomal RNA gene andthe nucleic acid sequences 5′ to this gene.

First, genomic DNA from MDCK cells (Accession No. CCL-34, ATCC) wasisolated using a MasterPure DNA Purification kit (EPICENTREBiotechnologies; Madison, Wis.). Sequence alignment indicates that 18SrRNA gene is about 90% identical in dog, human, mouse, rat, and chicken.A pair of primers were designed based on the sequences in the conservedregion near the 5′ end of 18S rRNA gene for PCR to amplify a ˜500 bpregion from MDCK genomic DNA as a probe to detect the digestionfragments on the membrane which has complementary sequences throughSouthern hybridization. A single restriction fragment was identified ingenomic DNA digested separately with BamH I (2.2 kb) and EcoR I (˜7.4kb). Both fragments were cloned into the pGEM 7 vector (Promega Corp.;Madison, Wis.) for further analysis. The plasmid containing the EcoR Ifragment was submitted for deposit with the American Type CultureCollection on Apr. 19, 2006, and was assigned A.T.C.C. Accession No.______.

The two clones obtained by restriction digestion analysis were alignedand the orientation of the two clones was confirmed by sequencing bothends of the two clones. A restriction map of the Eco RI fragment ispresented as FIG. 8. Next, the complete nucleic acid sequences of thefragment between the 5′ EcoR I site and the next BamH I site in the 3′direction was determined and assembled into a nucleotide sequencecontaining about 3530 bases. This sequence is presented as FIGS. 9A-C(SEQ ID NO: 1).

Next, primer extension experiments were performed to identify theinitial nucleotide of transcripts expressed from the canine RNA pol Iregulatory elements. Briefly, total RNA was isolated from MDCK cells. Alabeled oligonucleotide primer was annealed to the RNA and used to primeDNA synthesis towards the 5′ end of the 18s rRNA. To identify the firstnucleotide in the transcript, the same primer was used to sequence therRNA using a conventional dideoxynucleotide-based protocol By comparingthe length of the nucleic acid obtained in the primer extension to thevarious nucleic acids obtained in the sequencing reaction, the firstbase of the 18s rRNA could be identified. The first transcribednucleotide (the +1 position) is at base 1804 of the nucleotide sequencepresented as FIGS. 9A-C.

To confirm that the sequences upstream from this nucleotide containsufficient regulatory elements to direct transcription of downstreamgenes, a construct comprising an EGFP gene under control of theregulatory sequences was constructed using standard techniques. The EGFPgene used in this construct is the EGFP gene described in Hoffmann etal. (2000) “Ambisense ” approach for the generation of influenza Avirus: vRNA and mRNA synthesis from one template Virology15:267(2):310-7). This construct was then was transfected into MDCKcells using conventional techniques. 24 hours following transfection,RNA was isolated from the transfected cells and subjected to Northernblot analysis with a labeled DNA encoding an EGFP gene. Detection ofappropriately sized transcripts confirmed that the plasmids transfectedinto the MDCK cells contained regulatory sequences that directedtranscription of the sequences 3′ to the regulatory elements.

8.11 Example 11 Identification of Canine RNA Polymerase I RegulatoryElements

This example describes identification and characterization of a canineRNA polymerase I regulatory element, the canine RNA polymerase Ipromoter.

Canine RNA pol I promoters and other regulatory regions are identifiedby inspecting sequences 5′ to the initiation of transcription of the 18srRNA for canonical promoter sequences. Further, simple deletionexperiments are performed to identify the sequences required forefficient transcriptional initiation. In one such deletion experiment, arestriction site is introduced into or identified in a plasmid encodingthe nucleotide sequence of FIGS. 9A-C by site directed mutagenesis. Therestriction site is introduced about 50 nucleotides 3′ from the +1nucleotide identified above, nucleotide 1804 in the sequence presentedas FIGS. 9A-C. Another restriction site 5′ to the nucleotide sequence ofFIGS. 9A-C relative to the +1 position is identified or introduced bysite-directed mutagenesis.

The vectors containing these restriction sites are then linearized bydigestion with the appropriate restriction enzyme. Next, an appropriatenuclease (e.g., Exonuclease I, Exonuclease III, and the like) is used todigest the linear nucleic acids. By stopping the reaction at differenttime points, different sizes of deletions in the regions 5′ to the startof transcription can be obtained. Next, the linear plasmids arerecircularized and transformed into appropriate host cells, thenscreened to identify plasmids containing the desired deletions.Alternately, appropriate oligonucleotides can be synthesized thatcontain sequences flanking a deletion to be introduced. Sucholigonucleotides are then used to make derivatives containing loop-outdeletions using standard techniques. Oligonucleotides can also be usedto make site-directed substitutions using standard techniques.

The ability of the different deletion or substitution mutants toinitiate transcription is determined by transfecting the plasmids intoMDCK cells and detecting RNA transcribed from the plasmids by NorthernBlot as described above. By comparing the sequences of plasmids thatallow transcription with those that do not allow transcription, thesequence of the canine RNA polymerase I promoter is identified.Conventional techniques are then used to clone a nucleic acid encodingthis sequence.

Alternately, the canine RNA pol I promoter can be mapped from thenucleic acid provided as SEQ ID NO: 1 by other methods known in the art,e.g., by using a minigenome approach. See, e.g., published U.S.application 20050266026 for use of an influenza minigenome reporterdesignated pFlu-CAT, which contained the negative sense CAT gene clonedunder the control of the pol I promoter. Also see, EGFP minigenome inHoffinann et al. (2000) “Ambisense ” approach for the generation ofinfluenza A virus: vRNA and mRNA synthesis from one template Virology 15:267(2):310-7); and CAT minigenome system pPOLI-CAT-RT in Pleschka etal. (1996) J. Virol. 70(6):4188-4192.

To use these systems to identify and characterize the sequences requiredfor efficient transcriptional initiation, the differentdeletion/substitution mutants described above or other subsequences ofSEQ ID NO: 1 are introduced into the reporter plasmid selected (e.g.,PFlu-CAT, the EGFP minigenome) such that transcription of anegative-sense copy of the reporter gene depends on initiation oftranscription by the deletion or substitution mutant. TheEGFP-containing construct described above can conveniently be used tomake such deletion or substitution mutants. Next, viral RNA-dependentRNA polymerase synthesizes positive-strand mRNA from the negative-strandRNA transcribed from the reporter plasmid. This positive-strand mRNA isthen translated by the cellular machinery so that the reporter protein(either EGFP or CAT) activity can be detected.

In the assays, a set of expression plasmids that contains the cDNAs ofPB1, PB2, PA and NP or PB1, PA, NP (−PB2 as a negative control) istransfected into MDCK cells together with a plasmid comprising aninfluenza A virus EGFP minigenome or the pFlu-CAT reporter under thecontrol of a putative canine Pol I regulatory sequence. The cells arethen cultured under conditions that permit transcription and translationof the reporter sequence.

Activity of the reporter protein is detected using conventionaltechniques. In the case of EGFP, the transfected cells are observedunder phase contrast microscope or fluorescence microscope at 48 hourspost-transfection. Alternatively, flow cytometry is employed to detectEGFP expression. In assays with a minigenome comprising the CAT gene,designated pFlu-CAT is utilized to measure polymerase activity. In suchan assay, CAT expression is measured by detecting the CAT proteindirectly (e.g., by ELISA), by detecting mRNA encoding CAT (e.g., byNorthern blot), or by detecting CAT activity (e.g., detecting transferof radiolabeled acetyl groups to an appropriate substrate) as anindicator of reporter activity.

For example, the DNA fragments from the MDCK clone which had exhibitedpromoter activity (see primer extension and transcription assays above)were cloned upstream of an insert which contained influenza 5′ and 3′untranslated regions fused to the 5′ and 3′ ends, respectively, of anegative sense EGFP gene followed by a murine Pol I terminator (See,FIG. 11). Three separate constructs were made which differed in theinserted MDCK sequences: MDCK sequences 1-1802 (−1), 1-1803 (+1) and1-1804 (+2) of SEQ ID NO:1. Each of these constructs were separatelycombined with expression plasmids for influenza replication proteins(PB1, PB2, PA and NP) and electroporated into MDCK cells. At 24 hourspost-electroporation, the cells were examined by fluorescencemicroscopy. As shown in FIG. 12, all three MDCK fragments, −1, +1 and +2(top left, middle and right, respectively) resulted in EGFP fluorescencewhile the construct lacking promoter activity exhibited only backgroundfluorescence (bottom left). The 1-1803 (+1) fragment resulted in thehighest level of fluorescence. A plasmid with a CMV promoter drivingexpression of EGFP is used as a positive control (bottom right).

Influenza replication proteins will only replicate authentic influenzavRNA ends. The EGFP signal from each of the plasmids containing an MDCKpol I sequence indicates that the canine regulatory sequence fragmentscontained promoter activity which produced a RNA with correct influenzavRNA ends capable of supporting influenza replication.

Other assays useful for identifying and characterizing the canine RNApol I regulatory sequences include RNA foot-printing experiments. Insuch procedures, RNA molecules comprising, e.g., the sequence presentedin FIGS. 9A-C, are contacted to one or more subunits of canine RNApolymerase I. The one or more subunits of canine RNA pol I bind toappropriate RNA sequences according to their particular affinities.Next, an RNAse, e.g., RNAse I, is used to degrade RNA unprotected by theone or more subunits of canine RNA polymerase. The RNAse is theninactivated and the protected RNA fragments isolated from the protectingone or more subunits of RNA polymerase I. The isolated fragments containsequences bound by the one or more subunits of RNA polymerase I and areexcellent candidates for sequences having promoter/enhancer activity.Further, these foot-printing experiments can be performed in thepresence of different subunits of canine RNA polymerase I to identifywhich subunit binds which RNA sequence. These experiments can help todetermine the activity of the different bound sequences by, e.g.,comparing the sequences of the different canine Pol I polymerasesubunits to RNA polymerase I subunits from other species with knownsequences and binding specificities.

In vitro techniques can also be used to monitor transcription fromputative canine pol I regulatory sequences. In these techniques, thedifferent deletion/substitution mutants described above or othersubsequences of SEQ ID NO: 1 are operably linked to a transcript ofinterest. The set of canine RNA polymerase I proteins required fortranscription are then added to the transcripts. Effective transcriptionis detected by detecting the RNA transcript made by the canine RNApolymerase I proteins by, e.g., Northern blotting.

Similar assays can be used to identify other canine RNA pol I regulatoryelements, e.g., enhancer, repressor, or other elements that affecttranscription by RNA pol I. Generally, in such assays, expression levelsfrom reporter constructs comprising deletions, substitutions, orsubsequences of SEQ ID NO.: 1 are compared to expression levels from aminimal RNA pol I promoter identified as described above. By comparingthe expression levels, the presence of an element associated withenhanced or decreased transcription can be identified.

8.12 Example 12 Influenza Rescue in MDCK Cells

This example describes use of the canine RNA pol I regulatory elementscloned in Example 10 to rescue influenza virus in MDCK cell culture.

Expression vectors encoding viral genomic RNAs under the control of thecanine RNA pol I promoter and/or other nucleic acids of the inventionpresent upstream from the 18s rRNA gene are constructed usingconventional molecular biology techniques. Such constructs are used torescue influenza virus in MDCK cells.

Further guidance on protocols for using expression plasmids to expressinfluenza proteins and genomic RNA in order to obtain viral RNAassociated with proteins that yield infectious viral particles whenintroduced into appropriate cells may be found, e.g., in U.S. Pat. Nos.5,578,473, 5,576,199, 5,820,871, 5,854,037, International PatentPublication No. WO/0060050, and U.S. Patent Publication Nos.2002/0164770 and 2004/01422003, each of which is hereby incorporated byreference in its entirety.

While the foregoing invention has been described in some detail forpurposes of clarity and understanding, it will be clear to one skilledin the art from a reading of this disclosure that various changes inform and detail can be made without departing from the true scope of theinvention. For example, all the techniques and apparatus described abovemay be used in various combinations. All publications, patents, patentapplications, or other documents cited in this application areincorporated by reference in their entirety for all purposes to the sameextent as if each individual publication, patent, patent application, orother document were individually indicated to be incorporated byreference for all purposes.

1. An isolated nucleic acid comprising a canine RNA polymerase Iregulatory sequence.
 2. The nucleic acid of claim 1, wherein theregulatory sequence is a promoter.
 3. The nucleic acid of claim 1,wherein the RNA polymerase I regulatory sequence comprises nucleotides 1to 1803 of SEQ ID NO: 1 or a functionally active fragment thereof. 4.The nucleic acid of claim 1, 2 or 3, wherein the regulatory sequence isoperably linked to cDNA encoding a negative-strand viral genomic RNA orthe corresponding cRNA.
 5. The nucleic acid of claim 4, wherein thenucleic acid further comprises a transcription termination sequence. 6.The nucleic acid of claim 5, wherein the negative-strand viral genomicRNA is an influenza genomic RNA.
 7. An expression vector comprising thenucleic acid of claim
 6. 8. A method for producing an influenza genomicRNA, comprising transcribing the nucleic acid of claim 6, therebyproducing an influenza genomic RNA.
 9. A method for producing arecombinant influenza virus, comprising culturing a canine cellcomprising the expression vector of claim 7 and one or more expressionvectors that express an mRNA encoding one or more influenza polypeptideselected from the group consisting of: PB2, PB1, PA, HA, NP, NA, Ml, M2,NS1, and NS2; and isolating the recombinant influenza virus.
 10. Themethod of claim 9, wherein influenza virus produced is infectious. 11.The method of claim 9, wherein the method results in the production ofat least 1×10³ PFU/ml influenza viruses.
 12. A cell comprising theexpression vector of claim
 7. 13. The cell of claim 12, wherein the cellis a canine cell.
 14. The canine cell of claim 13, wherein the caninecell is a kidney cell.
 15. The canine kidney cell of claim 14, whereinthe canine kidney cell is an MDCK cell.
 16. A method for generating incultured canine cells a recombinant segmented negative-strand RNA virushaving greater than 3 genomic vRNA segments, said method comprising: (a)introducing into a population of canine cells a first set of expressionvectors capable of expressing in said cells genomic vRNA segments toprovide the complete genomic vRNA segments of said virus; (b)introducing into said cells a second set of expression vectors capableof expressing mRNA encoding one or more polypeptides of said virus; and(c) culturing said cells whereby viral particles are produced.
 17. Themethod of claim 16, wherein infectious influenza viral particles areproduced.
 18. A method for generating in cultured canine cellsinfectious influenza viral particles, said method comprising: (a)introducing into a population of canine cells a set of expressionvectors capable of expressing in said cells i) genomic vRNA segments toprovide the complete genomic vRNA segments of said virus and (ii) mRNAencoding one or more polypeptides of said virus; (b) culturing saidcells whereby said viral particles are produced.
 19. A virus produced bythe method of claim
 16. 20. The method of claim 16, 17 or 18, whereinhelper virus is used.